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Many common diseases such as obesity and type-2 diabetes have a significant
genetic component that contributes to susceptibility.  Peroxisome proliferator activated
receptors (PPARs) are nuclear receptors that heterodimerize with the retinoid X
receptors (RXRs) to influence the expression of many genes involved in adipocyte
differentiation and lipid metabolism such as the fatty acid binding proteins (FABPs) and
the uncoupling proteins (UCPs).  Genetic variation in any of these gene families could
potentially alter metabolic traits related to obesity and type-2 diabetes.  The goal of this
project is to identify genetic variation in the PPARs and RXRs and then to determine if
this variation is associated to quantitative traits related to obesity and type-2 diabetes
using a multi-locus analysis approach.  In this study, three sets of regression models
were constructed: the first containing polymorphisms in just the PPARs or RXRs; the
second with variants from all four gene families; and the third using polymorphisms from
the gene isoforms showing the highest level of expression in each of three tissues.
Some of the models were only able to account for small portions of the particular trait
variation; however, many of the models accounted for a large amount of variation in the
trait, up to 23.4% in the Hispanic female model for fasting free fatty acids.  Multi-locus
genotypes, as opposed to single locus effects, were found to be the best predictors of
variation in almost all of the final models.  These analyses confirmed the importance of
iv
gene-gene interactions on traits related to obesity and type-2 diabetes such as fasting
free fatty acids and cholesterol; therefore, multiple polymorphisms should be considered
together to fully understand their influence on a quantitative trait.
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1I. Specific Aims
Peroxisome proliferator activated receptors (PPARs) are nuclear receptors that are
activated by fatty acids and their derivatives.  They act as transcription factors to
influence the expression of many genes involved in fatty acid metabolism and adipocyte
differentiation.  PPARs must form heteroduplexes with the retinoid X receptors (RXRs)
before binding to the PPAR response elements (PPREs) in the 5' promoter sequence of
the genes that they regulate.  Sequence variations in either the PPAR or RXR genes
could alter the transcriptional activity, heteroduplex formation, ligand binding, DNA
binding or overall stability of the molecules.  Genetic variation could also alter regulation
of the genes the PPAR:RXR heterodimer controls such as the fatty acid binding proteins
(FABPs) or the uncoupling proteins (UCPs).  Any of these changes could alter the
balance between energy intake and energy expenditure contributing to obesity and/ or
type-2 diabetes.  Therefore, it is of interest to analyze genetic variation in these genes
to determine if they are important factors contributing to obesity or diabetes in the
general population.  Also, since the RXRs, FABPs, and UCPs are all involved in the
PPAR regulatory pathway, there is a potential for interactions between genetic
variations in any of these genes that could further contribute to the obese or diabetic
phenotype.  The specific aims for this project are:
1. To identify common single nucleotide polymorphisms in the promoter, coding
sequence or flanking sequences of the genes PPARα, PPARβ, PPARγ,
RXRα, and RXRβ.
22. To genotype a sample of 764 individuals participating in the San Luis Valley
Diabetes Study for the variations identified in the genes of interest.
3. To test for associations between single locus genotypes and quantitative
traits related to obesity and type-2 diabetes and to test for gene-gene
interactions by building regression models including genotypic data from
polymorphisms in the PPARs, RXRs, FABPs, and UCPs.
3II. Background and Significance
A. Genetics of Complex Disease
Many common diseases including obesity, diabetes, and coronary artery disease
have a significant genetic component that contributes to susceptibility.  It is vital that we
understand the biological basis of susceptibility for these common disorders in order to
develop rational strategies for treatment and prevention.  By identifying genetic factors
that influence the risk for common disorders, we can gain a clearer understanding of
their etiology and develop more effective interventions.  However, common disorders
present a new challenge to geneticists.  These disorders have both genetic and
environmental factors contributing to disease risk and severity.  In most cases, the
genetic component is thought to be polygenic with many genes having a small effect on
risk.  In addition, disease susceptibility is genetically heterogeneous both within and
between ethnic groups.  Gene-gene and gene-environment interactions are also likely
to play an important role in the development of these disorders.
Traditional approaches to finding susceptibility loci for complex diseases have
not been as successful as when they are applied to monogenic disorders.  In a review
of 101 linkage studies looking at complex disorders, more than 66% failed to find
significant linkage based on the criteria proposed by Lander and Kruglyak (Lander,
1995; Altmuller, 2001).  Even when linkage was detected, the significant results within a
given disease were often inconsistent (Altmuller, 2001).  New techniques need to be
developed that are better able to model a polygenic trait.  Several groups have found
4multiple polymorphisms within a region to be associated with disorders like type-2
diabetes and Crohn’s disease, highlighting the need to look at various sites in
combination (Gura, 2001).  Researchers are in the process of developing new
strategies to do just that.  The combinatorial partitioning method (CPM) compares all
possible genotypic groupings (or partitions) of multiple loci to variation in a quantitative
trait in order to determine the most predictive partitions (Nelson, 2001).  Unfortunately,
questions remain as to the biological significance of these partitions and, as this is a
new technology, its availability to the scientific community is limited.  Another method
based on the CPM, multifactor-dimensionality reduction, is applicable to case-control
studies and is computationally more simple but suffers from the same limitations as the
CPM (Ritchie, 2001).  In addition, scientists have recently begun a new project to
construct a haplotype map of the human genome in order to reduce the number of
polymorphisms that need to be typed while still retaining most of the genetic information
(Helmuth, 2001).  In the future, these techniques will likely help us to elucidate the
genetics of complex disease, but for now variations on more traditional methods should
be explored.
1. Obesity
 Obesity is a very common and important health problem in the world, especially
in the US.  Over one third of Americans are considered overweight or obese by current
clinical guidelines (body weight ≥ 120% of ideal body weight) (Solomon, 1997).  When
height is taken into consideration, approximately 20% of US men and 25% of US
5women are considered obese, with a body-mass index (BMI, calculated as kg/m2)
greater than 30 (Kopelman, 2000).  Obesity has a severe impact on public health
because of its association with other diseases such as hypertension, cardiovascular
disease, cancer, and type-2 diabetes (Friedman, 2000).  The risk for developing most of
these conditions increases not only with greater amounts of excess adipose tissue but
also with a central deposition of the fat, a region linked to increased lipolysis and fatty
acid production (Pi-Sunyer, 1993;Jensen, 1997).
Obesity occurs when energy intake exceeds energy expenditure and the surplus
energy is stored as fat in adipose tissue.  In addition to environmental influences such
as dietary content and physical activity, there are many physiological pathways that
regulate energy balance.  Insulin and leptin, two adiposity hormones, circulate at levels
corresponding to an individual’s body fat and stimulate the central nervous system
(CNS) to reduce energy intake thereby helping to regulate weight gain when adipose
stores are at sufficient levels (Schwartz, 2000).  However, many obese individuals are
both insulin and leptin resistant and require higher levels of the hormones, and therefore
adipose tissue, to produce a response by the CNS (Friedman, 2000).  Increased
adipose tissue lipolysis and subsequent elevation of free fatty acids is also associated
with insulin resistance (Kopelman, 2000).  In addition, energy expenditure in the form of
heat is under close physiological control and disruptions in these thermogenic pathways
are thought to contribute to the development of obesity (Lowell, 2000).
6Mutations in genes such as leptin, the leptin receptor and the melanocortin-4
receptor can lead to monogenic forms of obesity, but these simple genetic forms of
obesity are very rare in the general population (Barsh, 2000).  Many potential
susceptibility loci for obesity have been identified through various forms of linkage
studies.  Human chromosome regions such as 2p (pro-opiomelanocortin), 7q15
(neuropeptide Y), 7q31 (leptin), 10p, and 20q13 have been linked to obesity traits (Bray,
1999; Hager, 1998; Lee, 1999).  When potential human homologs for mouse qualitative
traits are included in the list of potential obesity susceptibility loci, every human
chromosome except the Y chromosome shows at least one region of interest (Barsh,
2000).  Another approach to finding genes contributing to obesity is to identify
polymorphisms in candidate genes known to regulate energy balance then look for
associations with obese phenotypes.  The candidate gene approach has identified a
long list of possible obesity related genes, but the results of these candidate gene
association studies have been inconsistent among various populations and in some
cases the functional significance of the identified polymorphism is questionable (Barsh,
2000).
2. Type-2 Diabetes
Type-2 diabetes mellitus or non-insulin dependant diabetes mellitus occurs when
glucose homeostasis is altered due to impaired insulin action on peripheral tissues and/
or abnormal insulin secretion (Kahn, 1998).  Type-2 diabetes is the major cause of
blindness, renal failure and lower limb amputations in adults and is showing an
7increasing prevalence in most populations (O’Rahilly, 1997).  Obesity, family history,
diet and physical inactivity are all major risk factors for developing type-2 diabetes
Metabolic changes such as insulin resistance, dyslipidaemia and high blood pressure
are other risk factors that often appear before the clinical disease is evident (Groop,
1997).  Elevated levels of free fatty acids are also a strong predictor of diabetes and
correlate with hepatic glucose output, a major cause of diabetic hyperglycemia
(Bergman, 2000; Saltiel, 1996).  In addition, high levels of circulating free fatty acids
have been shown to cause pancreatic β cell apoptosis in obese rats linking increased
adipocyte lipolysis to diabetic pancreatic dysfunction (Shimabukuro, 1998).
Several human monogenic forms of diabetes have been identified including:
maturity-onset diabetes of the young (MODY) which can be caused by mutations in the
glucokinase gene; extreme insulin resistance caused by a defective insulin receptor
gene; and the diabetes-deafness and optic atrophy syndrome which is due to defects in
mitochondrial genes (Kahn, 1996). However, studies of animal models have
demonstrated the polygenic nature of this disease.  Mice with a phenotype similar to
human type-2 diabetes generally have mutations in two or more genes (Hussain, 1997).
In addition, studies in the Pima Indian population of Arizona have shown the importance
of gene-environment interactions in the development of type-2 diabetes in humans
which further complicates the search for genetic causes of this disease (Pratley, 1998).
Thiazolidinediones (TZDs) are a class of insulin sensitizing compounds that
include the drugs ciglitazone, troglitazone, and pioglitazone (Saltiel, 1996).  TZDs are
8capable of improving insulin action in a variety of insulin resistant animal models,
independent of the cause.  In humans, TZDs result in a 20% to 40% reduction in insulin
resistance although their effect on glucose disposal seems variable (Olefsky, 2000).
TZDs also improve many of the abnormalities associated with the insulin resistance
syndrome by lowering triglyceride levels, increasing HDL levels, and lowering blood
pressure (Olefsky, 2000).  It has been found that TZDs act as agonists for the
peroxisome proliferator activated receptor gamma, a member of the nuclear receptor
superfamily (Spiegelman, 1998).
B. Nuclear Receptors
The nuclear receptor superfamily is a group of proteins that act as transcription
factors to alter gene expression when bound to specific ligands.  They are involved in a
wide variety of functions such as lipid metabolism, embryonic development, and virtually
all endocrine pathways.  The physical structure of most nuclear receptors is very similar
and include four major regions: an NH2-terminal region with ligand-independent
activation properties, a core with two zinc finger motifs for specific DNA binding, a hinge
region for protein flexibility, and a COOH-terminal region with several binding domains
for ligands, dimers and activators (Chawla, 2001).  The superfamily can be broken down
into two groups: type I are the steroid receptors such as the estrogen receptor and
androgen receptor while type II contains the orphan receptors (liver X receptors (LXRs),
peroxisome proliferator activated receptors (PPARs), etc.) as well as the thyroid
hormone receptors (TRs), Vitamin D receptor (VDR), retinoic acid receptors (RARs),
9and the retinoid X receptors (RXRs) (Kastner, 1995).  Type I receptors form
homodimers and bind to palindromic repeats only in the presence of ligand while type II
receptors can form either homodimers or, more often, heterodimers and bind to direct
repeats with or without ligand (McKenna, 1999).  Many of the type II nuclear receptors
form heterodimers with the RXRs in order to bind with their appropriate response
elements and the PPARs, in particular, are only functional as heterodimers
(Mangelsdorf, 1995).
1. Retinoid X Receptors
There are three retinoid X receptor genes in humans, RXRα, β, and γ, found on
chromosomes 9, 6 and 1 respectively (Li, 2000; Numasawa, 1999; Rebhan, 1997).  In
adults, RXRβ is expressed ubiquitously, with RXRα found mainly in the liver, kidney and
skin and RXRγ in muscle and heart (Rowe, 1997).  The RXRs can form homodimers as
well as heterodimers with other nuclear receptors like PPARs, RARs, LXRs, VDR and
TRs.  Interestingly, the crystal structure of the RXRα:PPARγ heterodimer suggests that
the heterodimeric state is more permissive than the homodimer (Gampe, 2000).
The only known natural ligand for the RXRs is 9-cis retinoic acid, a metabolite of
vitamin A, although the presence of this ligand is not required for most RXR
heterodimers to be active (Mangelsdorf, 1995).  Several other substances, such as
phytanic acid, methoprene acid, are also capable of activating the RXRs and a series of
synthetic drugs called rexinoids have been developed to influence lipid homeostasis
10
through the RXRs (Chawla, 2001).  In apolipoprotein E knockout mice, activation of
RXRs by rexinoids caused a dramatic reduction in atherosclerotic lesion size at least
partly through the PPAR and LXR signaling pathways (Claudel, 2001).
The RXRβ gene contains 10 exons and spans 6.2kb at 6p21.3 near HLA class II.
Numasawa et al screened the coding sequence of the RXRβ gene to look for variation
associated with ectopic bone formation and discovered three polymorphisms in or near
the gene (Numasawa, 1999).  The first site, a T to A substitution, is in the 3’
untranslated region of exon 10.  The other variants are in the intergeneic region
between RXRβ and collagen 112A at +140bp (A to T) and +561bp (C insertion/deletion)
after the 3’ end of exon 10.  The allele frequencies for these three polymorphisms in
Japanese controls are given in Table 1.
Table 1: Allele Frequencies for RXRβ Polymorphisms
Polymorphism Allele Frequency # of Individuals
RXRb10 (T/A) q=0.07 (A) 158
RXRb+140 (A/T) q=0.23 (T) 158
RXRb+561 (C/CC) q=0.17 (CC) 131
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2. PPAR:RXR Heterodimer
The PPAR:RXR heterodimer exists in both an active and inactive state.  When
inactive, it is bound to corepressors such as the nuclear receptor corepressor (N-CoR)
or the silencing mediator for retinoid and thyroid hormone receptor (SMRT) (DiRenzo,
1997).  In the presence of ligand for either PPAR or RXR, the corepressors dissociate
so that the ligand can bind and activate the complex.  Activity of the complex is thought
to increase in the presence of both a PPAR and a RXR ligand although both are not
necessary.  PPAR ligands include fatty acids and their derivatives as well as several
synthetic compounds while the only known natural ligand for RXR is 9-cis retinoic acid
(Desvergne, 1999).  PPARs can also show enhanced activity in the presence of
coactivators that phosphorylate a specific site on the protein.  At least two of the three
isotypes (PPARα and PPARγ) show increased activity when phosphorylated in
response to insulin (Juge-Aubry, 1999; Shalev, 1996).  When the PPAR:RXR complex
is activated, it binds to a PPAR response element (PPRE) in the 5’region of target
genes to induce transcription. PPREs consist of two direct repeats of AGGTCA
separated by one base, called a DR-1 element, although the 5’ flanking region is also
important for proper binding since the PPAR:RXR complex is polar and binds in a
specific direction (Desvergne, 1998).
12
3. Peroxisome Proliferator Activated Receptors
Peroxisome proliferator activated receptors regulate a number of cellular
functions from fatty acid oxidation to adipocyte differentiation.  They were first identified
as proteins that induce peroxisome proliferation in rodent liver cells in response to
exogenous chemicals, many of which are hepatocarcinogens.  There are three PPAR
isotypes; α, β (or δ) and γ, which have somewhat different expression patterns and
functions.  All three types have similar gene structures consisting of six coding exons
and two 5’ untranslated exons.  The PPARγ gene has a third 5’ exon that is specific for
the γ2 isoform and encodes for an additional 28 amino acids (Beamer, 1997; Fajas,
1997).  In addition to directly regulating gene expression by complexing with the RXRs,
PPARs can also act as negative regulators of gene transcription by interacting with
other transcription factors, like NF-κB, to form inactive complexes thereby inhibiting the
normal function of the other protein (Gervois, 2000).
a) PPARα
PPARα is found primarily in the liver and regulates genes involved with fatty acid
utilization.  The gene for PPARα is located on chromosome 22 and has one main
isoform (Sher, 1993).  A splice variant lacking exon 6 is found in the liver, but its
function is unknown (Palmer, 1998).  Other than the liver, PPARα is also expressed at
significant levels in skeletal muscle, kidney, heart and small intestine (Auboeuf, 1997;
Mukherjee, 1997).  Elevated glucocorticoids cause an increase in PPARα expression
levels (Auboeuf, 1997; Mukherjee, 1997) and physical activity also seems to generate
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higher levels of the protein (Horowitz, 2000).  Insulin causes activation of the protein
through phosphorylation, but down regulates PPARα expression (Desvergne, 1999;
Shalev, 1996).  Ethanol, however, seems to reduce activity and could relate PPARα to
the development of fat accumulation in alcoholic liver diease (Torra, 2001).  Activation
of PPARα by fibrates, a common hypolipidemic drug, causes a decrease in circulating
lipid levels in humans (Gervois, 2000).  On the other hand, PPARα null mice show
hyperlipidemia and obesity associated with ageing in a sexually dimorphic pattern with
females showing higher levels for the traits (Costet, 1998).  Under fasting conditions,
PPARα null mice show hypoglycemia, hypothermia, increased plasma free fatty acids
levels and an accumulation of lipids in the liver due to their inability to degrade fatty
acids (Pineda Torra, 2001).
PPARα regulates the expression of genes involved in the peroxisomal and
mitochondrial β-oxidation pathways such as acyl-CoA oxidase, enoyl-CoA
hydratase/dehydrogenase multifunctional enzyme, keto-acyl-CoA thiolase, malic
enzyme, medium chain acyl-CoA dehydrogenase, and mitochondrial hydroxy
methylglutaryl-CoA synthase (Schoonjans, 1996a).  PPARα also regulates fatty acid
transporter protein (FATP), fatty acid translocase (FAT), fatty acid binding proteins
(FABPs) and uncoupling proteins 2 and 3 (UCP2 and UCP3) (Bernlohr, 1997: Brun,
1999; Desvergne, 1999; Motojima, 1998).  By altering transcription of these genes,
activated PPARα leads to increased breakdown of triglycerides and fatty acids,
increased cellular fatty acid uptake, and reduced triglyceride and fatty acid synthesis
(Schoonjans, 1996b).
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In a study of 165 diabetic individuals (Mexican American and Caucasian), Au, et.
al. screened the PPARα gene and found several single nucleotide polymorphisms (Au,
1998).  Many of the SNPs were at very low frequencies and/ or conservative or intronic;
however, two missense mutations were identified.  The first, is a C to G substitution in
codon 162 of exon 5 which changes a leucine to a valine at a frequency of q=0.054 for
the G allele.  The other variant is a substitution of a T (valine) for a C (alanine) in codon
223 of exon 6 with the rare allele at a frequency of q=0.015 (Au, 1998).  The valine
allele of the L162V polymorphism has been associated with increased levels of
apolipoprotein B, total cholesterol, HDL cholesterol and apolipoprotein A1 in type-2
diabetics and increased Apo B and LDL cholesterol in non-diabetic individuals (Vohl,
2000; Flavell, 2000).  This allele has also been reported to show ligand-concentration
dependant variation in activation.  The response of V162 in the absence of ligand and at
low ligand levels was much lower than the L162 form, but at high ligand levels, the V162
variant showed greater transactivation activity than L162 (Sapone, 2000; Flavell, 2000).
b) PPARβ
Less is known about PPARβ, also referred to as PPAR δ, NUC1 and FAAR.  The
expression of PPARβ is widespread and it is found at moderate levels in most tissues,
with high levels of the protein found in the placenta and large intestine (Auboeuf, 1997;
Mukherjee, 1997).  The gene for PPARβ is located on chromosome 6 and encodes one
known isoform.  PPARβ is thought to help regulate many of the genes that the other two
PPARs influence including the FABPs, FAT and acyl-CoA synthase in the intestines
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(Bernlohr, 1997; Desvergne, 1999).  The PPARβ-null mouse shows the importance of
this protein in normal development.  Mice lacking the PPARβ protein are growth
retarded, have low myelination in their central nervous system and show reduced
adipocyte mass (Chawla, 2001).  This loss of adipocye mass is likely due to a direct
effect of PPARβ on adipogenesis.  Overexpression of PPARβ in preadipose cells
causes an increase in the adipogenic response to fatty acids while a dominant negative
mutant form of the receptor shows an extremely muted response to fatty acids (Bastie,
2000; Jehl-Pietri, 2000).  PPARβ has also been found to be a direct regulator of PPARγ
gene expression (Hansen, 2001; Bastie, 1999).  Therefore, PPARβ activation by
nutritional fatty acids appears to induce PPARγ expression that then stimulates
adipogenesis upon activation.
c) PPARγ
PPARγ is an important regulator of adipocyte differentiation and function.  The
gene for PPARγ is located on chromosome 3 and codes for three distinct isoforms
(Green, 1995).  PPARγ1 and PPARγ3 are regulated by separate promoters, but differ
only in their transcription initiation start site so the mature proteins are identical.
Recently, a fourth isoform, PPARγ4, was identified with a separate promoter just 5’ of
exon 1 which also results in a mature protein identical to the γ1 and γ3 isoforms
(Sundvold, 2001).  These isoforms are located in several tissues including adipose
tissue, liver, muscle and heart.  The PPARγ2 isoform is regulated by its own promoter
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and has a unique first exon.  It is only found at low levels in adipocytes and possibly
skeletal muscle cells.  In adipocytes, PPARγ is activated by fatty acids and stimulates
genes involved in fatty acid release, transport, and synthesis such as lipoprotein lipase
(LPL), FAT, FATP, the FABPs, acyl-CoA synthase, malic enzyme and
phosphoenolpyruvate carboxykinase (PEPCK) (Motojima, 1998; Schoonjans, 1996a).  It
also reduces the expression of leptin, a potent satiety factor (Schoonjans, 1997).
Expression of the insulin sensitive glucose transporter, GLUT4, and the UCPs are also
influenced by PPARγ (Kelly, 1998; Wu, 1998).
Expression of PPARγ is induced by both insulin and corticosteroids (Vidal-Puig,
1997), but is down-regulated by TNF-α, IFNγ and other inflammatory cytokines which
causes de-differentiation of adipocytes (Xing, 1997; Tanaka, 1999; Hogan, 2001).  In
mice, a high fat diet will also induce PPARγ expression (Vidal-Puig, 1996).  Increased
levels of PPARγ have also been detected in the skeletal muscle of obese subjects both
with and without NIDDM in relation to BMI and fasting insulin (Kruszynska, 1998).  On
the other hand, heterozygous PPARγ-deficient mice show adipocyte hypertrophy and
normal insulin sensitivity even when fed a high fat diet (Kubota, 1999).  PPARγ null mice
are non-viable due to placental and cardiac defects (Barak, 1999).  Even though PPARγ
is of obvious importance in lipid and glucose homeostasis, it has also been implicated in
many other cellular functions including carcinogenesis, inflammation, and
atherosclerosis due to its interactions with many of the compounds listed above
(Auwerx, 1999).
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Several genetic variations have been described in the human PPARγ gene.  The
P115Q conversion, first identified in 4 morbidly obese subjects, causes defective
phosphorylation of the protein resulting in accelerated adipocyte differentiation (Ristow,
1998).  Two other mutations (P467L and V290M) were found in 3 individuals (in 2
families) with severe insulin resistance, dyslipidaemia and hypertension.  Both of these
mutations have been shown to cause impaired ligand-dependant transactivation and
inhibit wild-type PPARγ in a dominant negative manner (Barroso, 1999).  Two other
more common polymorphisms, a silent C to T substitution in exon 6 and a C (proline) to
G (alanine) substitution at codon 12, have also been reported in PPARγ (Vigouroux,
1998; Yen, 1997).  The frequencies of these polymorphisms in several populations are
shown in Table 2 below.  There is evidence that suggests that the mutant protein
produced by the alanine allele at codon 12 has reduced transcriptional and adipogenic,
activity in vitro, which could lead to lower adipose tissue mass (Masugi, 2000).  In
addition, the alanine allele was found to be associated with lower lipolysis and greater
insulin sensitivity in a group of lean non-diabetic subjects (Stumvoll, 2001).
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Table 2: Previously reported frequencies for the PPARγ polymorphisms
Polymorphism
Frequency of Less
Common Allele Population
0.12
26 Diabetic Caucasian Americans
(Yen, 1997)
0.10 36 Mexican Americans (Yen, 1997)
0.03 53 African Americans (Yen, 1997)
0.01 50 Chinese (Yen, 1997)
0.13 107 Finns (Valve, 1999)
0.03 215 Japanese Men (Mori, 1998)
0.18 312 Italians (Mancini, 1999)
0.15 973 Elderly Finns (Deeb, 1998)
0.11
686 Caucasian Americans (Beamer,
1998)
hPPARg2
(Pro12Ala)
0.11 839 French (Meiraeghe, 2000)
0.17
26 Diabetic Caucasian Americans
(Yen, 1997)
0.21 107 Finns (Valve, 1999)
PPARg6
0.14 820 French (Meiraeghe, 1998)
d) Genetic Association Studies of P12A
Many studies have examined the association between the P12A polymorphism
and various measures of obesity or diabetes, but the results have been variable.  Four
groups have shown an association between the Ala allele and increased BMI in
Caucasian or Mexican American samples (Beamer, 1998; Cole, 2000, Meiraeghe,
2000; Valve, 1999) while another study reports that the Ala allele is associated with
lower BMI in a large sample of Finnish individuals (Deeb, 1998) and five other studies
found no association with BMI (Douglas, 2001; Mancini 1999; Meirhaeghe, 1998; Mori,
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1998; Mori, 2001a).  Ek, et al found that the Ala allele was related to higher BMI in a
sample of obese Danish men, but lower BMI in the non-obese controls (Ek, 1999).
Some of these apparent inconsistencies can be explained by variations in study design,
study population, or methods of analysis and many of these studies lacked a sufficient
number of Ala homozygotes to accurately compare them to the other genotypes.  The
study samples varied in age, gender, ethnicity, and phenotypic definitions that may also
account for some of the discrepancies.  In addition, as the Ek study shows, other
variables seem to be influencing the phenotypic expression of this polymorphism that
simple analyses do not take into account.  By incorporating dietary measures into their
model, Luan, et al were able to detect an interaction between the ratio of
polyunsaturated fat to saturated fat and the Pro12 Ala polymorphism in relation to BMI
and fasting insulin (Luan, 2001).  These results may also explain some of the
inconsistencies of previous studies and support the use of more sophisticated analysis
techniques that can incorporate environmental variables.
Unlike the reports for BMI, a more consistent finding from many groups has been
that the Ala allele is associated with a decreased risk of type-2 diabetes.  Most notably,
in a large study of Scandinavian individuals, the P12A variation was the only
polymorphism out of 16 common SNPs that were previously reported to influence
diabetes risk to show a reproducible association with decreased diabetes risk.  Because
the detrimental allele is the more common proline (p~0.85) the modest genotype relative
risk of 1.25 for this sample is equivalent to a population attributable risk of 25%
(Altshuler, 2000).  A large case-control study of Japanese type-2 diabetics versus non-
20
diabetics also supports the conclusion that the A12 allele is protective against diabetes
(Hara, 2000).  The protective effect of the alanine allele correlates with the in vitro
findings of lower transactivating activity and increased insulin sensitivity.  However,
even this association is not without dispute.  In a study of the Canadian Oji-Cree, the
alanine allele of the P12A polymorphism was found to be associated with increased risk
for type-2 diabetes in women, but not in men (Hegele, 2000).  Thus, it is likely that the
Pro12Ala variation either has different consequences in distinct ethnic groups or else is
in varying linkage disequilibrium with another polymorphism that is also influencing
measures of obesity or diabetes.
C. Fatty Acid Binding Proteins
The cytoplasmic fatty acid binding proteins (FABPs) are among the most
abundant proteins in cells that metabolize lipids.  They bind to long chain fatty acids with
high affinity that can vary with chain length and degree of saturation (Bernlohr, 1997).
The FABPs are involved in fatty acid cellular uptake and intracellular transport and may
protect the cell from potentially detrimental effects of fatty acids by sequestering them
(Glatz, 1995).  In addition, liver FABP (FABP1) appears to be involved in the signaling
pathway for PPARα in the liver by delivering a fatty acid to the PPAR protein through a
direct interaction (Wolfrum, 2001).  Other FABPs have also been found to localize to the
nucleus in a ligand dependant manner suggesting that they may also act in a similar
manner to FABP1 and could be major players in PPAR signaling and regulation of fatty
acid levels (Glatz, 2001).
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There are at least eight distinct types of FABPs including FABP1 (liver), FABP2
(intestine), FABP3 (heart and skeletal muscle), FABP4 (adipose), FABP5 (epidermal),
FABP7 (brain), myelin FABP and ileal FABP (Glatz, 1995).  Most of these proteins are
only expressed in a single tissue as noted above; however, FABP1 is expressed in
several tissues other than liver and FABP3 is expressed in many tissues in addition to
heart and muscle (Bernlohr, 1997).  The gene structure of four exons separated by
three introns is conserved among the all of the FABPs.  The 5’ promoter region for at
least four of the FABPs (1, 2, 3, and 4) contain PPAR response elements suggesting
direct regulation of these genes by the PPARs (Bernlohr, 1997).
Several FABP knockout mice have been created to better understand the
function of these proteins.  The FABP2 null mouse develops hyperinsulinemia
independent of weight gain.  The male mice also show increased levels of serum
triacylglycerols and gain more weight than normal mice suggesting that FABP2 may be
influenced by sex hormones (Vassileva, 2000).  Similarly, a polymorphism has been
identified in the human FABP2 gene at codon 54 that substitutes a threonine for an
alanine and has been associated with insulin resistance and dislipidemias (Glatz, 2001).
The FABP3 deficient mice show decreased fatty acid uptake into heart and skeletal
muscle that is compensated for by increased glucose uptake and oxidation (Binas,
1999).  Mice that lack FABP4 have no obvious phenotype, but when fed a high fat diet,
they had lower insulin levels than control mice on the same diet (Shaughnessy, 2000).
22
D. Uncoupling Proteins
The uncoupling proteins (UCPs) were first discovered in mitochondria from
brown adipose tissue (BAT).  There, they divert energy from ATP synthesis by diffusing
the proton gradient across the mitochondrial inner membrane to produce heat (Gura,
1998).  Through this pathway, BAT is able to help regulate thermogenesis and fat
storage by burning calories instead of producing ATP.  In addition to UCP1, the BAT
isoform, two other major UCP isoforms have been identified, UCP2 and UCP3.  UCP2
and 3 have reduced thermogenic capabilities in BAT and are thought to have additional
or separate functions such as regulation of fatty acid oxidation or reactive oxygen
species production (Boss, 2000).  All three UCPs are regulated by the PPARs and
therefore, fatty acids, although the response varies depending on the PPAR and UCP
isotypes.  Two other isoforms have recently been identified in the brain, UCP4 and
UCP5 or brain mitochondrial carrier protein-1, but little is known about their function or
regulation other than that they are capable of uncoupling activity (Adams, 2000).
1. UCP1
The gene for UCP1 is located on chromosome 4 and contains 6 exons
(Dalgaard, 2001).  As previously noted, UCP1 is exclusively expressed in brown
adipose tissue which is well developed in human infants and adult rodents although only
trace amounts of BAT are detectable in adult humans (Pecqueur, 2001).  Mice deficient
for UCP1 are cold intolerant, but not obese although they show increased expression of
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UCP2 which could be compensating for the lack of UCP1 (Boss, 2000).  Fasting causes
a decrease in UCP1 mRNA expression in rats (Sivitz, 1998).
Because UCP1 is only expressed in BAT, it is difficult to determine the
importance of UCP1 in human disorders such as obesity and type-2 diabetes since
affected individuals should not have much, if any, BAT during the development of the
disease.  Two polymorphisms in linkage disequilibrium, an A to C transition in exon 1
and a Met229Leu substitution in exon 5, were both associated with susceptibility to
type-2 diabetes (Mori, 2001b).  Another variant was identified in exon 2 of the UCP1
gene that changes an alanine (G) to a threonine (A) at codon 64 (Urhammer, 1997a).
Also, an A to G substitution has been identified in the 5’ region of the UCP1 gene that
has been associated with reduced basal metabolic rate and ability to lose weight in
obese subjects when present with the Trp64Arg polymorphism in the β3-adrenergic
receptor (Valve, 1998; Fogelholm, 1998).  These studies suggest that UCP1 may be
important in adult onset disorders and should not be discounted simply because of its
limited expression.
2. UCP2
The UCP2 and UCP3 genes are both located on chromosome 11 separated by
approximately 7kb and contain 8 and 7 exons, respectively (Dalgaard, 2001).  UCP2 is
expressed ubiquitously but the highest levels are found in white adipose tissue
(Dalgaard, 2001).  Non-specific activation of PPARs in a myocyte cell line was found to
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slightly increase UCP2 expression while specific activation of PPARγ caused reduced
levels of UCP2 mRNA (Cabrero, 2000).  As further evidence of the complexity of the
PPARs regulation of UCP2, increased free fatty acid levels have been found to
correspond to higher UCP2 mRNA levels in rat muscles (Samec, 1999).  Obese
individuals have been found to show increased levels of UCP2 protein in skeletal
muscle that coincided with a reduced ability to use lipids (Simoneau, 1998).  UCP2 null
mice have no apparent physical phenotype and respond normally to cold exposure or a
high fat diet, possibly due to compensation by UCP1 in white adipose tissue.  They are,
however, resistant to infection by Toxoplasma gondii, a normally lethal pathogen, and
show an 80% increase in macrophage reactive oxygen species compared to wild-type
suggesting increased immunity in the absence of UCP2 (Arsenijevic, 2000).
Several variations in the UCP2 gene have been identified.  Urhammer, et al,
identified a substitution of a valine for an alanine at codon 55 in exon 4 (Urhammer,
1997b).  Also, a 45bp insertion/ deletion in the 3’ UTR of exon 8 has been associated
with increased BMI in one study, but not in another (Evans, 2000; Dalgaard, 1999).
Recently, Esterbauer et al identified 5 polymorphisms in the 5’ promoter region of the
UCP2 gene.  They found that for one of these, a G to A substitution at –866bp, the A
allele was associated with increased expression in vitro and reduced risk of obesity in
middle-age subjects (Esterbauer, 2001).
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3. UCP3
UCP3 is expressed at the highest levels in skeletal muscle and BAT, but is also
found in the heart (Samec, 1998).  Increases in free fatty acid levels induce UCP3
mRNA levels in rat muscle, probably through activation of the PPARs (Samec, 1999).
Carbacyclin, a non-selective PPAR ligand was found to increase UCP3 mRNA levels in
a myocyte cell line while specific activators of either PPARα or PPARγ had no effect
implicating PPARβ as the major regulator in this cell type (Nagase, 1999).  In another
study, PPARγ specific activators were found to reduce UCP3 mRNA levels in a different
myocyte cell line while PPARα specific and non-specific activators had no effect
(Cabrero, 2000).  Taken together, these results suggest that either the myocyte cell
lines have different responses to PPAR stimulation or, more likely, that there is a
complex interaction between the PPAR isotypes which have complementary effects on
UCP3 expression.  This is a plausible explanation knowing that PPARβ can alter PPARγ
expression as well as UCP3 expression and variation in ligand affinity between the
isotypes would complicate comparison of studies using different PPAR activators.  In
contrast to the findings in skeletal muscle, PPARα appears to be a potent stimulator of
UCP3 in rodent cardiac muscle (Young, 2001).  Also, PPARα and PPARγ show a
synergistic induction of UCP3 expression in rodent BAT (Teruel, 2000).
Mice with a deficiency in UCP3 are not obese on either a normal or high fat diets,
although they do have reduced proton leak across the mitochodrial membrane.  UCP3
knock-out mice also show increased levels of reactive oxygen species in skeletal
muscle, similar to UCP2 null mice (Dalgaard, 2001).  On the other hand, UCP3
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overexpressing mice are hyperphagic yet leaner than wild-type control animals.  While
this overexpression is specific to the skeletal muscle, the phenotype is seen outside of
this tissue in the form of reduced adipose tissue mass and lower insulin, glucose and
cholesterol levels (Clapham, 2000).
Many polymorphisms have been described in UCP3.  Argyropoulos et. al.
identified a V102I polymorphism in exon 3, a nonsense mutation in exon 4 (R143X), and
a splice variant in exon 6 in a group of obese and/ or diabetic African Americans
(Argyropoulos, 1998).  The R143X mutation and a missense mutation (R70W) were
both found to have severe to total loss of uncoupling activity while the V102I and splice
variant had normal activity (Brown, 1999).  Two additional polymorphisms were
identified, a T to C substitution in codon 99 of exon 3 and a C to T substitution in codon
210 of exon 5, that both conserve a tyrosine so are likely non-functional (Otabe, 1999).
Also, a C to T substitution at –55bp in the 5’ region of the UCP3 gene has been
associated with fasting glucose levels in males and percent body fat in females
(Yanagisawa, 2001).
E. The San Luis Valley Diabetes Study
The San Luis Valley Diabetes Study (SLVDS) is a geographically based case-
control study designed to identify risk factors for type-2 diabetes, heart disease and
obesity in a population of Hispanic and non-Hispanic whites living in Southern Colorado.
The study is based in two rural counties, Alamosa and Conejos, in the San Luis Valley
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of Colorado.  These counties are 43.6% Hispanic and have low immigration rates with
most families having lived there for several generations.  Diabetics were identified
through medical records and advertisment.  Then controls were selected from general
household interviews to reflect the distribution of the diabetic cohort.  The SLVDS
control cohort is comprised of 1280 individuals (1107 normal glucose tolerance and 173
impaired glucose tolerance) on whom metabolic, anthropometric and interview data was
collected over the course of three possible visits.  Informed consent was obtained from
all subjects and the University of Colorado Health Sciences Center institutional review
board approved all protocols.  Participants in the control cohort were 20-74 years old,
living in the San Louis Valley and had no reported history of diabetes at baseline.
Phase I and II clinic visits (baseline) were conducted between 1984 and 1988, Phase III
between 1988 and 1992, and Phase IV from 1997 to 1998.  The age adjusted
prevalence of type-2 diabetes (%) calculated from the Phase I data is shown in Table 3
(Hamman, 1989).
Table 3: Age adjusted prevalence of type-2 diabetes (%) in the SLVDS
Male Female
Hispanic 9.9% 10.7%
Non-Hispanic 4.5% 3.5%
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F. Summary
This review shows the obvious importance of the PPAR transcriptional pathway
in regulating adiposity and glucose homeostasis.  The PPARs control genes involved in
lipid and glucose homeostasis and are important regulators of adipogenesis.  Since the
RXRs are the obligate binding partners for the PPARs and the FABPs are couriers for
the PPAR ligands, they also become key components in these pathways.  In addition,
the UCPs, which are regulated by the PPARs, are directly involved in energy regulation.
Figure 1 depicts the relationship between these four genes families.  The purpose of
this project is to examine the effects of polymorphisms in these genes, as single locus
effects and two locus genotypic interactions, on measures of obesity and type-2
diabetes in a large sample of Hispanic and non-Hispanic white individuals from the San
Luis Valley Diabetes Study.
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Figure 1: Diagram of the PPAR Transcriptional Pathway
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III.  Methods and Materials
A. General Protocols
1. PCR
PCR reactions were optimized for each specific primer set, but a general protocol
was used in all cases.  All PCR reactions consisted of 0.5µM of each primer, 1x PCR
buffer (Gibco BRL), 1.25mM dNTPs (Gibco BRL), 5% DMSO (if necessary), 0.625U of
Taq DNA polymerase (Gibco BRL), and ~50 to 100ng of genomic DNA.  The MgCl2
concentration was specific for each primer set.  The reactions were amplified using
either a Hybaid Touchdown Thermal Cycler or an MJ PTC-100 Programable Thermal
Controller at the following conditions: initial denaturation at 95oC for 3 min.; 35 cycles of
95 oC for 30 sec., the annealing temperature (specific for each primer set) for 30 sec.,
and extension at 72 oC for 30 sec.; followed by a 5 min. extension at 72 oC.
Amplification of PCR products was confirmed by electrophoresis on a 1% agarose gel.
Optimization of particular primer sets was achieved by testing each primer set at three
different salt concentrations (1.0M, 1.5M and 2.5M MgCl2) and at various annealing
temperatures estimated from the predicted melting temperatures of the primers.
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2. Direct Sequencing
Sequencing reactions consisted of 4µl of ABI Prism dRhodamine Dye Terminator
Ready Reaction Mix, 4µl of 0.8mM primer and 4µl of PCR product.  The reactions were
run for 25 cycles on either a PE GeneAmp 9600 thermal cycler or an MJ PTC-100
Programable Thermal Controller under the following conditions: 96oC for 10 seconds,
50oC for 5 seconds, and 60oC for 4 minutes.  The DNA was then precipitated with 30µl
of a solution of 70% ethanol and 0.5mM MgCl2 for at least 2 hours at 4
0C before being
spun down at 2000 rpm for 30 minutes in an IEC Centra-7 centrifuge.  The ethanol was
then discarded and 3.5µl of formamide dye (see Appendix A) was added to each tube.
The products were then separated on an ABI Prism 377 DNA Sequencer and the output
was analyzed using Sequencher v3.1.1 by Genecodes.
3. Single Stranded Conformational Polymorphism Analysis
Single stranded conformational polymorphism analysis (SSCP) was used as an
alternate way to detect sequence variation in the genes of interest to ensure that all
variants were found (see Appendix A).  SSCP analysis followed the protocol of
Razzaghi and Kamboh (2001).  The PCR product (7.5µl) was combined with 3.75µl of
denaturing solution and incubated at 42oC for 10 minutes.  The reactions were
immediately transferred to ice where 3.75µl of formamide dye was added to each
reaction.  Each sample was then loaded into a well of a 20% 15-Well TBE Pre-Cast
polyacrylamide gel (Novex) and run at 150V at 4oC on a Mighty Small II Vertical
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Electrophoresis Unit (Hoefer) until both dye fronts were run off.  The gels were then
stained with SYBR Green II RNA Gel Stain (Molecular Probes Inc.) for 20 to 30 minutes
in the dark before being photographed.
4. Oligonucleotide Ligation Assay
Polymorphisms that did not alter a restriction enzyme site were genotyped using
the oligonucleotide ligation assay (OLA) (see Appendix B) (Nickerson, 1990).  First, the
PCR product was diluted 1:1 with 0.1% triton in deionized water.  A ligation reaction
mixture was then made for each allele consisting of 2mM NAD, 2x ligase buffer, 0.058%
triton water, 25mM KCl, 0.1 µM of the oligonucleotide unique to the allele, 0.1 µM of the
common oligonucleotide and 0.1unit of ampligase.  The unique oligonucleotides were
labeled on the 5’ end with biotin while the common oligonucleotide was labeled 3’ with
digoxygenin.  Two reactions were created for each PCR product, one for each allele, by
mixing 10µl of one ligation reaction mixture with 10µl of the diluted PCR product and
repeating this in the adjacent well with the other ligation reaction mix.  Ligation reactions
were then carried out for ten cycles at 93oC for 30 seconds and 58oC for 2 minutes on a
Hybaid Touchdown Thermal Cycler.  In a reaction where the DNA matches the unique
oligonucleotide, the unique and common oilgos are ligated together to form a longer
oligonucleotide labeled with biotin (5’) and digoxigenin (3’).  If the DNA allele does not
match the unique oligonucleotide, the probes will not be ligated and will remain
separated from each other.  Next, 10µl of stop solution was added and the entire
reaction was transferred to 96-well flat bottom plates that were coated with strepavidin
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and blocked with BSA.  The strepavidin captures the biotinylated oligonucleotides and
binds them to the plate while the unligated common oligos remain free in solution.  After
incubating for ~30 minutes at room temperature, the plates were washed two times with
0.1M NaOH wash and twice with 0.1M Tris wash.  Then, 40µl of anti-digoxigen antibody
solution was added to each well and allowed to sit for 25 to 30 minutes before being
washed again six times with 0.1M Tris wash.  An ELISA substrate was then added
(25µl) and after 15 minutes an equal amount of amplifier was also added.  A solution of
sulfuric acid at a concentration 0.3M was used to stop the ELISA color change reaction
when the plates were readable.  Wells containing ligated oligonucleotides (unique +
common) show a positive reaction (pink color) and are considered to contain DNA with
the allele specified in the ligation reaction mixture.  On the other hand, the digoxigenin
labeled common probe is washed away when it is not ligated to the unique oligo so
these wells show a negative reaction (clear color).  A negative reaction is read as a lack
of the allele specified in the ligation reaction.
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B. Screening and Identification of Variation
1. PPARβ
No variation had been previously reported in the PPARβ gene so it was screened
using single-stranded conformational polymorphism analysis (SSCP) and direct
sequencing.  Primers were designed in the introns of the gene to cover the translated
regions of the sequence and in the promoter region to cover approximately 1kb of
sequence immediately 5’ of exon 1A (see Table 4).  Sequence and genomic structure
were derived from the human clone 109F14 on chromosome 6p21.2-21.3 (Genbank
accession #AL022721, http://www.ncbi.nlm.nih.gov).  Several exons were amplified in
multiple overlapping pieces in order to keep the PCR products within a size range for
efficient SSCP.  Standard PCR reaction conditions were used (see Table 4).  Screening
was preformed on 11 control samples in order to detect common variations.
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Table 4: Primers and PCR conditions used for amplification of PPARβ
Fragment
Name
Gene
Region Forward and Reverse Primer
Anneal
-ing
Temp.
MgCl
Conc. DMSO
PPARB p1 5’
F-cgcaggctccgcagaattct
R-ctccaggaggcgtggtgattg
60oC 1.0M
PPARB p2 5’
F-cgagacgtcaccgcgctg
R-gagcgccaggtccagtagaaca 64
oC 2.5M
PPARB p3 5’
F-gatgcggacgtagcagctaag
R-gacctagcactgggttaagagtc 58
oC 1.5M
PPARB p4 5’
F-ggtacgtgacttgcagtgacaag
R-gcgtattgcataagcacatgg 58
oC 1.5M
PPARB 2 Exon 2
F–tcagaggaacaactggcata
R–ctctccaccacatttctaccaa 52
 oC 2.5M
PPARB 3-1 Exon 3
F–ctgtggctgctccatggct
R–tcctcttccttgtcactgcctc
56oC 2.5M Yes
PPARB 3-2 Exon 3
F–actgcactgggctgtgcct
R–ccgaggggagatcagccatg
58 oC 1.0M Yes
PPARB 4 Exon 4
F–gaccacagcctcagtggccagc
R–ggcctggcagcatgtggagc
64 oC 2.5M
PPARB 5 Exon 5
F–ctgtgtggagccagcagccc
R–ctccctcctcctggtggcctt
66 oC 2.5M
PPARB 6-1 Exon 6
F–ggtcggccacctgtgggttgt
R–cctgcctgggctccttgctg
53 oC 2.5M Yes
PPARB 6-2 Exon 6
F–ccaggatgctgccaggccaa
R–tgaaggccttctccaagcacatctacaat
60 oC 2.5M Yes
PPARB 7-1a Exon 7
F–ctcaatgatatcactgaagggtttgcg
R–gcgtgcacgaggccatcttc 60
 oC 1.0M Yes
PPARB 7-1b Exon 7
F–gactgggtgtgccaggccag
R–ctaagtttgaatttgctgtcaacg 57
 oC 1.5M Yes
PPARB 7-2a Exon 7
F–ccgtccttgttcacgatagaggc
R–gctgccagtgcaccacagtg 58
 oC 1.5M Yes
PPARB 7-2b Exon 7
F–ggtagaagacgtgcacgctgatct
R–ggtctcccgaggcctgatctc 58
 oC 1.5M Yes
PPARB 8-1 Exon 8
F–cattggagtctgcagggaggc
R–acctgcatgccaaccaccct 63
 oC 1.5M Yes
PPARB 8-2 Exon 8
F–gcaggtcagccatcttctgca
R–ggagctccactgcctttctgag 58
 oC 1.5M Yes
Primer sequences are listed 5’ to 3’ for both forward (F) and reverse (R) primers.
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2. RXRα
No variation had been previously reported in RXRα.  It was screened for
common variations using SSCP and direct sequencing.  PCR products were designed
to cover the coding sequence of the gene in 200 to 250bp amplimers based on
sequence obtained from Genbank (accession #AQ917567, AQ917569, AQ917571,
AQ917573, AQ917575, AQ917577, AQ917579, AQ917581, AQ917566, AQ917568,
AQ917570, AQ917572, AQ917574, AQ917576, AQ917578, AQ917580 and
NM_002957).  Twelve to sixteen normal control samples were screened by both
detection methods for exons 2 through 10.  See Table 5 for the PCR conditions and
primer sequences.
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Table 5: Primers and PCR conditions used for amplification of RXRA
Fragment
Name
Gene
Region
Forward and Reverse Primer
Annealing
Temp.
MgCl
Conc.
RXRA 2a Exon 2
F-ctgcactgaccactctcctgc
R-gagctgatgaccgagaaaggc 58
oC 1.0M
RXRA 2b Exon 2
F-cagctgcattctcccatcag
R-ctgcagttgaagccacagcc 60
oC 1.0M
RXRA 3 Exon 3
F-ggacatagggacaaacctggtg
R-cctgcaatggcctgacaac 54
oC 1.5M
RXRA 4 Exon 4
F-tcaagcggacggtgcgca
R-ccatctcgggtgtccacgca
58oC 1.0M
RXRA 5 Exon 5
F-gctgagcgtggggctcacct
R-gaggcatgtgaggctgcccac
64oC 1.5M
RXRA 6 Exon 6
F-ggactgaatgtcctgctcttct
R-tggtacgtgtcccatctgc
54oC 1.5M
RXRA 7 Exon 7
F-gcctggagacagctgagtgactg
R-ggcggaggtgaccgaagc
54oC 1.5M
RXRA 8 Exon 8
F-tggtgagggctgcgacctaac
R-acggggccagaagcctcaa
54oC 1.5M
RXRA 9 Exon 9
F-ccagctgagggttctgacc
R-gagacaagagcctgggtctg
58oC 1.0M
  Primer sequences are listed 5’ to 3’ for both forward (F) and reverse (R) primers.
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3. Promoter Regions
The 5’ regions of the PPARα and PPARγ genes were also screened for variation.
Approximately 1kb of sequence immediately 5’ of exon 1 for PPARα and exon B (γ2
specific) for PPARγ was screened using SSCP and direct sequencing.  Four
overlapping primer sets were designed for each of the regions based on the reported
sequence (Genbank accenssion #Z94161 and AB00520).  At the time of the screening,
the PPARγ1 promoter had not been characterized and only 125bp of sequence was
available for primer design so this region was not investigated in this project.  Twelve
control individuals were screened to identify common variation.  PCR reaction
conditions are reported in Table 6.
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Table 6: Primers and PCR conditions used for amplification of the PPAR promoter
regions
Fragment
Name
Gene
Region
Forward and Reverse Primer
Annealing
Temp.
MgCl
Conc.
PPARA p1
α
promoter
F-agggccctgagcttcagcct
R-agcctccttgggataagggtgc 64
oC 1.5M
PPARA p2
α
promoter
F-caaggaggctgggagaggagg
R-accccaaccgggcacaact 60
oC 1.5M
PPARA p3
α
promoter
F-ggcagggccgaccctcctgac
R-gaccccggacaggctgcgct 64
oC 1.5M
PPARA p4
α
promoter
F-acccggcccagcgcagcct
R-gcggtcgccgactcagaaggtgct
64oC 1.0M
PPARG2 p1
γ2
promoter
F-gtcttgactcatgggtgtattc
R-agtgtatcagtgaaggaatcgc
60oC 1.5M
PPARG2 p2
γ2
promoter
F-cagctggctcctaataggaca
R-ctatctagcaaaagatcaatccgt 60
oC 2.5M
PPARG2 p3
γ2
promoter
F-tacagttcacgcccctcac
R-ggagagatgggaataaacacag
60oC 2.5M
PPARG2 p4
γ2
promoter
F-agattcaaccaggaatagacacc
R-cggtgacccacatgttcag 60
oC 2.5M
  Primer sequences are listed 5’ to 3’ for both forward (F) and reverse (R) primers.
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C. Genotyping
1. Study Population
The San Luis Valley Diabetes Study (SLVDS) was designed to explore the risk
factors for type-2 diabetes in Hispanic and Non-Hispanic White individuals living in rural
southern Colorado.  Metabolic, anthropometric and interview data was collected over
the course of three possible visits.  The Phase I and Phase II clinic visits are considered
the baseline visits and were conducted between 1984 and 1988.  The Phase III and
Phase IV follow up clinic visits were conducted from 1988 to 1992 and 1997 to 1998,
respectively (see Figure 2).  The SLVDS control cohort consisted of 1270 subjects who
had no previous history of diabetes and were not diabetic based on a 75g oral glucose
tolerance test at the time of the baseline clinic exam (WHO, 1985).  Individuals were
only included in the genotyping if they participated in the Phase Four visit and had DNA
available.  Development of type-2 diabetes was possible during the 9 to 14 years
between the baseline visit, when the controls were classified as non-diabetic, and the
Phase IV visit.  Individuals who were diagnosed with type-2 diabetes during the Phase
IV visit were not excluded from this study.  Of the 764 individuals who were included in
the genotyping, 321 subjects were Hispanic (H) and 443 were Non-Hispanic whites
(NH) based on self-reported ethnicity.
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Figure 2: Timeline of the SLVDS clinic visits
2. PPARα
Several polymorphisms have been identified in PPARα by Au, et. al. (1998).
One of these sites is a C (leucine) to G (valine) substitution found at nucleotide 700 of
the mRNA that corresponds to codon 162 in exon 5 of the PPARα gene (Genbank
accession #L02932).  Another site, found in exon 6 at nucleotide 896 of the mRNA, is a
T to C substitution that changes a valine to an alanine at codon 223 (Genbank
accession #L02932).  These particular sites were chosen for further analysis in this
study because they showed the highest frequencies of the exonic polymorphisms that
were reported.  Neither of these polymorphisms altered a restriction enzyme site so they
were genotyped using OLA.  PCR conditions and primer sequences can be found in
Table 7.  These polymorphisms will be referred to as PPARa5 (exon 5 variant) and
PPARa6 (exon 6 variant) in this report.
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Table 7: Primers and PCR conditions for OLA genotyping for PPARα variants
PPARa5 PPARa6
Forward PCR
Primer
ttctttcggcgaacgattcg ctgaaagcagaaattcttacctgt
Reverse PCR
Primer cgttgtgtgacatcccgacag ttgttactggcctttcctgag
Annealing Temp. 56oC 56oC
MgCl Conc. 2.5M 2.5M
P
C
R
 C
on
di
tio
ns
DMSO Yes Yes
Common
Detection Primer
tttctgtcgggatgtcacac-D catcctctcaggaaaggcca-D
Allele Specific
Primer #1
B-ttgtcgatttcacaagtgcC B-aacaaggtcaaagcccgggT
O
LA
 P
rim
er
s
Allele Specific
Primer #2 B-ttgtcgatttcacaagtgcG B-aacaaggtcaaagcccgggC
Primer sequences are listed 5’ to 3’ for both forward (F) and reverse (R) primers.
Abbreviations: B – biotin; D – digoxigenin
3. PPARβ
A silent C to T substitution located at nucleotide 72054 (Genbank accession #
AL022721) was detected in exon 6 of the PPARβ gene.  This polymorphism, called
PPARb6, was typed using an engineered NdeI restriction enzyme site (see Table 8).
The digestion reaction consisted of 2U of NdeI, 1x NEB buffer 4 and 10µL of PCR
product.  The reaction was left at 37oC overnight and then run out on a 2% agarose gel
to separate the fragments.  A fragment of 236bp corresponded to the C allele and two
fragments of 213bp and 23bp corresponded to the T allele.
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Table 8: Primers and PCR conditions for RFLP genotyping
Variant Forward and Reverse Primers
Anneal-
ing
Temp.
MgCl
Conc.
PPARb6
F-ctcccggagtcaggcaggcg
R-ctggtggcagggctgac
58oC 1.5M
PPARg2
F-gccaattcaagcccagtc
R-gatatgtttgcagacagtgtatcagtgaaggaatcgctttccg
50oC 1.5M
PPARg6
F-gatgagttgcttggtagagctg
R-cgggtgaagactcatgtctgt
58oC 1.5M
RXRb10 &
RXRb+140
F-tgagaagtccagggcagaac
R-ctgcagaaggaggtgaagt 60
oC 1.5M
     Primer sequences are listed 5’ to 3’ for both forward (F) and reverse (R) primers.
4. PPARγ
Two polymorphisms have been previously reported in the PPARγ gene.  The first
site is in the γ2 specific exon (exon B), at nucleotide 892 (Genbank accession
#AB005520).  The more common C allele corresponds to a proline at amino acid
position 12 while the G allele encodes for an alanine.  This polymorphism, henceforth
referred to as PPARg2, was detected through an engineered BstUI restriction enzyme
digestion (2.5U of BstUI, 1xNEB buffer 2, and 10µL of PCR product) that was incubated
at 60oC overnight.  The digested DNA fragments were resolved on a 2% agarose gel
and visualized under ultra violet light in the presence of ethidium bromide (see Table 8).
The resulting fragments were either 270bp (C Allele) or 227bp and 43bp (G Allele) when
compared to a DNA size standard.
44
The other polymorphism in PPARγ is located in exon 6 at nucleotide 268
(Genbank accession #AB005526).  This C to T substitution, referred to as PPARg6 in
this report, leads to the introduction of a NlaIII restriction site that was used to detect the
polymorphism (see Table 8).  The digestion reaction contained 2U of NlaIII, 1xNEB
buffer 4, 1µg BSA, and 10µL of PCR product that was then kept at 37oC overnight.  The
resulting fragments were then viewed on a 2% agarose gel.  The C allele resulted in a
fragment of 313bp and the T allele gave fragments of 270bp and 43bp.
5. RXRβ
Two polymorphisms have been reported in the RXRβ gene, one in the 3’ untranslated
region of exon 10 and one 140bp after the 3' end of the gene.  These sites will be
referred to as RXRb10 and RXRb+140 in this report.  The two sites are close enough
together to be amplified in one product of 442bp (see Table 8).  The first site, a T to A
substitution at nucleotide 7266 introduces a unique DdeI restriction site (Genbank
accession #AF120161).  Fifteen µL of RXRβ PCR product was digested with 1U of DdeI
and 1x Promega buffer D.  This results in fragments of size 440bp for the T allele and
319bp and 121bp for the A allele.  The A to T substitution at nucleotide 7412 introduces
a second MboI site into the PCR fragment that can be used for detection (Genbank
accession #AF120161).  This digestion reaction contained 1U of MboI, 1x React 2
buffer and 15µL of the RXRβ PCR product.  Fragments of size 398bp and 42bp
correspond to the A allele and of size 225bp, 173bp, and 42bp for the T allele.
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D. Data Analysis
1. Genotype Coding
Several numerical variables were used to represent the genotype data (see
Table 9).  First, a three category variable was made for each polymorphism using 1 for
the common homozygote, 2 for the heterozygote and 3 for the less common
homozygote. Because all of the polymorphisms have low frequencies, variables were
created for each site with 2 categories where the heterozygous individuals were
combined with those homozygous for the less common allele.  These assume a
dominant effect of the common allele and were labeled as PPARa5d, PPARa6d,
PPARb6d, etc.  Also, for some of the regression analyses, PPARb6 and RXRb+140
were common enough to look at all three genotypes so they were coded into 2 separate
dummy variables.  The first of these had the common homozygote equal to 1 and all
other genotypes equal to 0 and were labeled as PPARb6v1 or RXRb140v1.  The
second variable, PPARb6v2 or RXRb140v2, had the heterozygotes equal to 1 and all
other genotypes as 0.
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Table 9: Genotype Variable Coding for Regression Analysis
Genotype
Three Category
Variable
Dominant
Variable
First Dummy
Variable
Second Dummy
Variable
Common
Homozygote
1 1 1 0
Heterzygote 2 0 0 1
Less Common
Homozygote
3 0 0 0
2. Variables Used in Analysis
Three variables were initially chosen as outcomes for this study: body mass
index (BMI), fat mass (FM) as measured by DEXA, and fasting free fatty acid levels
(FFA).  BMI, calculated as weight in kilograms divided by the square of height in meters
(kg/m2), is a standard measure of general obesity used in many studies and is included
in this analysis to allow comparison with the findings of other studies.  Fat mass is a
more direct measure of adiposity and as the PPARs, PPARγ in particular, are known to
influence adipogenesis and fat storage, it is of obvious interest in this study.  In the
SLVDS, fat mass has been measured by dual energy x-ray absorptiometry (DEXA)
using a LUNAR DPX-L scanner, a method that measures body fat within soft tissues
independent of age, body water or the chemical content of the tissue (Pierson, 1991).
The PPAR:RXR heterodimers are also major regulators of fatty acid metabolism so
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genetic variation in these genes could alter blood levels of free fatty acids.  Fasting free
fatty acid levels (µmol/L) were measured from blood samples.
Other variables were included in the analysis as possible predictors, including
percent body fat, lean body mass, HOMA IR, total cholesterol, triglycerides, systolic
blood pressure, diastolic blood pressure, smoking, physical activity, total caloric intake,
total fat intake, ethnicity, age, and sex.  Percent body fat was calculated as the percent
fat mass (measured by DEXA) of the whole body mass.  Lean body mass represents
the amount of non-fat mass in an individual’s body and is calculated as the difference
between the total body mass and the fat mass in grams measured by DEXA.  HOMA IR
is a measure of insulin resistance based on the fasting insulin and glucose levels
[HOMA IR= (fasting insulin * fasting glucose)/ 22.5].  It is highly correlated with insulin
and glucose levels and was used instead of the fasting, 1 hour and 2 hour insulin and
glucose levels (Matthews, 1985).  Total cholesterol (mg/dl) and triglycerides (mg/dl)
were measured from blood samples.  The two separate readings were averaged for the
systolic and diastolic blood pressure measurements (mM).  Smoking status was
classified in three categories: 1 for non-smokers, 2 for current smokers, and 3 for ex-
smokers.  When smoking was used as an adjustment in the regression models, it was
recoded into two categories (1=non-smoker, 2=current smokers and ex-smokers) and
was referred to as “ever smoke”.  METS was used for the physical activity data and is
equal to the total physical activity over one week measured in kCal/kg/hr.  Dietary
measures were based on a recall interview of food intake for the previous 24 hours.
Ethnicity was based on self-declared status as either a Hispanic or non-Hispanic white.
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Skin reflectance measured by a portable spectrophotometer was used as a surrogate
for ethnicity during certain analyses (Gardner, 1984).  Age at the time of the Phase IV
clinic visit was used.
3. Descriptive Statistics
Allele frequencies were estimated for all typed polymorphisms and then tested
for fit to the expectations of Hardy-Weinberg equilibrium by the Χ2 test using Microsoft
Excel.  The EH program was used to determine estimated haplotype frequencies with
association (Ott, 2001).  D’ was then calculated between each pair of loci as a measure
of linkage disequilibrium (Hartl, 2000; Devlin, 1995).
All other statistical analyses were done using the SPSS statistical analysis
software package, version 10.0 for Macintosh.  All descriptive analyses were done on
two sets of the data: the entire data set and the data set split by ethnicity.  This results
in three groups of individuals: un-split, Hispanics, and non-Hispanics.
Descriptive statistics were calculated for all of the variables.  Frequencies were
determined for each of the categorical variables (genotypes, sex, ethnicity, and
smoking) that were then graphed as bar charts.  The Χ2 test was used to determine if
there were any ethnic differences in the frequencies of the categorical variables.
Several statistical measures were calculated for the continuous variables including
mean, standard deviation, standard error of the mean, skewness, kurtosis, and range.
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Histograms of the distributions for each of the continuous variables were also graphed
and a t-test was used to determine if there were any differences between the ethnic
groups.  Outcome variables with a skewness or kurtosis value greater than one were
transformed with the natural log and the descriptive statistics were re-calculated.
Outliers were determined based on the descriptive statistics and histograms.
Seventeen extreme outliers who were likely the result of incorrect measurements or
data entry errors were excluded from all further analyses.  These individuals were ID#
252, 749, 3077, 3169, 3194, 3137, 3195, 3243, 3348, 3467, 3592, 3645, 3757, 3759,
3776, 3878, and 3953.  Exclusion of these individuals did not substantially change the
descriptive statistics for any of the variables.
4. Univariate Analysis of Predictor Variables
All of the predictor variables were tested for associations with the outcome
variables (BMI, FM, FFA).  One-way analysis of variance (ANOVA) was used to test for
associations between the outcome variables and the categorical variables.  Linear
regression was used to test the relationship between the continuous variables and the
outcome variables.
In order to determine colinearity between the predictor variables, all of the
predictor variables were tested against each other.  A Χ2 test was used to look for
relationships between pairs of categorical variables.  Associations between categorical
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variables and continuous variables were determined with one-way ANOVA.  Bivariate
correlations were calculated for all combinations of continuous variables.
5. New Outcome Variables
The results of the univariate analyses suggested that other variables might be of
more interest than the outcome variables originally selected.  The ANOVA tests did not
show any significant relationships between the genotype variables and two of the
outcomes, BMI and fat mass, for any of the groups.  Fasting free fatty acids did show
significant associations with some of the polymorphisms so it was retained as an
outcome variable.  As there were other continuous variables, notably fasting glucose
and cholesterol, found in the predictor correlation analyses that also showed association
with some of the variants, these variables were used as outcomes in the regression
analyses.  Both of these variables are plausible outcomes based on the known biology
of the PPARs and RXRs as these genes are involved in regulation of both cholesterol
and glucose metabolism.  Fasting glucose was not normally distributed so it was
transformed using the natural log.
6. Univariate Analysis with New Outcome Variables
Because sex was also an important predictor for the outcome variables, the next
set of analyses was done split by sex and ethnicity as well as un-split and split by only
ethnicity.  This resulted in seven groups of individuals: un-split SLVDS (U), Hispanics
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(H), non-Hispanics (NH), Hispanic males (H M), Hispanic females (H F), non-Hispanic
males (NH M), and non-Hispanic females (NH F).
One-way ANOVA was used to determine which genotypes were associated with
the outcomes in each of the seven groups.  Then, all pair-wise combinations of the
polymorphisms were tested by two-way ANOVA to determine any interesting interaction
effects.  The results of these analyses were then used to build regression models for
each of the outcomes in each of the groups as described below.
7. Regression Modeling
Models were constructed for each outcome in each group of individuals by
following a series of steps (see Figure 3).  Step 1 was to pick the polymorphisms to
include in each of the preliminary models.  Loci were included in the regression model if
they were significantly associated with the outcome (p<0.05) by one-way ANOVA or if
they were part of an interaction term with a p-value of less than 0.20 from a two-way
ANOVA test.  All possible pair-wise combinations of the single loci picked for each
model were also included in the preliminary model as interactions.  The interaction
terms were calculated by multiplying the two single locus genotype variables together.
This resulted in interaction terms that contrasted the double common homozygotes with
all other genotype combinations.
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Figure 3: Diagram of Regression Modeling Process
The next step (Step 2) was to use linear regression to test the preliminary
models.  All models were tested using both a stepwise and backward approach to
modeling.  The stepwise approach entered significant terms one-by-one and re-tested
each term after the addition of a new term.  The backward approach entered all of the
terms into the model then removed the non-significant terms one-by-one.  Entry and
removal criteria were set at a p-value of 0.05 and 0.051, respectively.  Cases were
excluded listwise from the analysis.  Residual statistics and descriptive statistics were
calculated for each model.  In step 3, the regression models were re-tested but only
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included the terms that remained in either the stepwise or backward model from step 2.
If the models did not agree after this step, they were re-tested with the remaining terms
from the models in step 3.  This was continued until the stepwise and backward models
retained the same terms (Step 4).  At times, the backward models retained terms that
the stepwise did not and no agreement could be reach using the above criteria.  In this
case, the backward model was used as the final model because it allows for multiple
terms to be retained that are dependant on each other.
Finally, step 5 was to construct a final model for each of the groups and
outcomes.  Terms were entered into the final model if they appeared in the final
backward and stepwise model as well as any corresponding dummy variable.  Each of
the terms in the final model was graphed to visualize the effect on the outcome variable.
It should be noted that no correction was made for multiple testing in this analysis as it
is exploratory.  Results from this study were based on consistencies within the analysis
as a whole and should be replicated in other studies for confirmation.
8. Combined Analysis with UCPs and FABPs
Models were constructed that combined the previously developed models for the
PPARs and RXRs with models including polymorphisms in the UCP and FABP genes.
Coleen Damcott went through a similar process as described above to construct models
for fasting free fatty acids and cholesterol in the SLVDS sample split by sex and
ethnicity (Damcott, unpublished data, 2001; see Appendix F).  The eleven sites used for
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this analysis were UCP1-2, UCP2-4, UCP2-8, UCP3-5, UCP3p-55, FABP2pID,
FABP2p-834, FABP3pID, FABP3p-313, FABP4-2b, and FABP4p-376.
The combined models were constructed for fasting free fatty acids and
cholesterol in the four ethnic/sex groups since there were corresponding models from
the PPAR/RXR and UCP/FABP analyses.  Sites were included for this analysis if they
met any of the following criteria: 1) Present in the final model from the previous analysis
for that outcome, 2) Oneway ANOVA with a p-value <0.05, or 3) Interaction term from
previous paired ANOVA with a p-value of <0.15.  The sites which met one of these
criteria were then tested against all of the sites in the other group by 2-way ANOVA
(PPARs and RXRs vs. UCPs and FABPs).  A list of possible terms for the regression
analysis was constructed that included the sites that met the inclusion criteria for the 2-
way ANOVAs and the sites from the 2-way ANOVA that had an interaction term with a
p-value <0.15.  Sites were excluded from this list based on their p-values and the
number of times they appeared, until a reasonable number of terms (<40) were left to
test in the regression model.  More weight was given to sites and interactions with a p-
value <0.05.  The list of terms included in the regression analysis always included main
effect terms and interactions from the previous models and all possible interactions
between the two sets of polymorphisms (PPARs and RXRs vs. UCPs and FABPs).  The
same process for determining the final model in the previous analysis was used to make
final models for each of the ethnic/ sex groups for both outcome variables.  Final models
included both sets of any dummy variables.  The terms from the final models were
graphed to visualize the effect.
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9. Tissue Specific Covariate Models
Tissue specific regression models were also constructed for several adjusted
outcome variables.  Models were constructed for the muscle, adipose tissue and
intestines using polymorphisms from the genes that have the highest expression in that
particular tissue.  Muscle models included terms from PPARα, UCP3, and FABP3.
Adipose models included PPARγ, UCP 1, UCP2, and FABP4 sites.  Intestinal models
tested sites from PPARβ, UCP2, and FABP2.  The outcome variables tested in this
analysis were fat mass and lean mass.  These variables were adjusted for skin
reflectance, smoking (ever smoke), age and physical activity by saving the
unstandardized residuals from a regression model of the outcome versus those
covariates.  The covariates were entered into the adjustment model regardless of their
effect to ensure that as much environmental variation as possible was removed.  Skin
reflectance was used as a measure of ethnicity in order to account for the admixture
between Europeans and Native Americans that is present in the Hispanic population.
The other covariates were included in this analysis due to their potential effect on the
outcomes and their lack of an obvious genetic component.  The mean value for each
unadjusted outcome was then added to the unstandardized residuals to compute the
adjusted values.  From this point on, all analyses were carried out on the SLVDS data
set, split by sex.
Regression models were then constructed for each outcome in each tissue with
the tissue specific sites noted above as well as all possible interactions.  The models
were tested in both a stepwise and backward manner until they matched at which point,
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they were considered final models.  In some cases, the backward models kept sets of
terms that were dependant on each other and that the stepwise models did not
consider.  When this occurred, the backward model was considered the final model.
After the models were constructed for each tissue, overall models were constructed
based on the final models for each tissue.  All of the terms that appeared in each final
tissue specific model plus all single locus terms that appeared in interactions were
tested for the overall models.  Models were constructed for each of the outcome
variables in both sexes.  All terms from the models were then graphed to visualize the
effects.
E. Other Analysis
1. PPARb6
During the analysis to construct multi-locus models, PPARb6 was noted to have
a particularly strong effect by itself on fasting glucose, fasting insulin and HOMA IR as
tested by one-way analysis of variance.  To further explore this effect, regression
models were constructed for ln(fasting glucose), ln(fasting insulin) and ln(HOMA IR)
containing PPARb6, sex and skin reflectance as a measure of ethnicity.  Stepwise and
backward approaches were used to test the regression models until they resulted in the
same model that was then considered the final model.
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2. Analysis of PPARγ Polymorphisms
The two polymorphisms in PPARγ, PPARg2 and PPARg6, have been associated
with various measures of obesity and type-2 diabetes in other studies that have
assumed the effect is attributable to the PPARg2 amino acid substitution.  A separate
set of analysis was done to determine the relative contribution of each of these
polymorphisms to several obesity and diabetes related traits.  The outcome variables
(fasting glucose, fasting insulin, HOMA IR, fasting free fatty acids, fat mass, and percent
fat) were adjusted for skin reflectance using linear regression then the mean of the
unadjusted outcome was added to the unstandardized residuals to get the adjusted
values for each outcome.  One-way analysis of variance was then used to test the effect
of each site on the adjusted outcomes for males and females.  Next, regression models
were constructed for the traits showing association with at least one of the
polymorphisms to determine the effect of each variant alone and in combination.  The
outcomes used in this analysis were fasting glucose, fasting insulin and HOMA IR which
were adjusted for skin reflectance, fat mass, smoking (ever smoke) and age.  Separate
models were tested for PPARg2 alone, PPARg6 alone and both sites plus the
interaction.
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IV. Results
A. Screening and Identification of Variation
1. PPARβ
The PPARβ gene was screened for variation using single-stranded
conformational polymorphism analysis (SSCP) and direct sequencing.  Exons 2, 3, 4, 5,
6, 7 and 8 were screened in eleven samples and one polymorphism was identified in
exon 6 (see Figure 4 and Figure 5).  This silent C to T substitution, PPARb6, is located
at nucleotide 72054 (Genbank accession # AL022721) and was genotyped using an
engineered NdeI restriction enzyme site.  Of the eight screening samples with reliable
genotypes there were four individuals with the TT genotype, three heterozygous
individuals and one CC individual giving an estimated allele frequency of 0.31 for the
less common C allele.
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Figure 4: SSCP Gel for PPARb6 Variant
                      
   CC Homozygote                CT Heterozygote                   TT Homozygote
Figure 5: Sequence Chromatograms of the PPARb6 Variant
CC TT CT
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2. RXRα and promoter regions
The gene for RXRα was screened for common variations using SSCP and direct
sequencing.  Exons 2 through 9 were successfully screened in 12 to 16 samples and no
polymorphisms were identified.  Approximately 1kb of the region 5’ of the first exon was
screened for PPARα, PPARβ and PPARγ (γ2 promoter).  No polymorphisms were
identified in any of these promoter regions in 16 individuals screened.
B. Genotyping
Seven polymorphisms were identified either from previous reports or from the
screening described above, and these were genotyped in 764 individual from the
SLVDS population (see Figure 6 and Figure 7).  There were two sites in PPARα
(PPARa5 and PPARa6) one site in PPARβ (PPARb6) two sites in PPARγ (PPARg2 and
PPARg6) and two sites in RXRβ (RXRb10 and RXRb+140).  All seven of the typed sites
conformed well to Hardy-Weinberg expectations in both the Hispanic (H) and Non-
Hispanic (NH) subsets of the SLVDS population (see Table 10 and Table 11).  The
allele frequencies for the PPARa5 T (Val) allele, typed by OLA, were 0.08 in NH and
0.11 in H.  The PPARa6 G (Ala) allele, also typed by OLA, was very rare in the NH
group at a frequency of 0.009 and was slightly more common in the H group (q=0.04)
although no GG homozygotes were identified in either ethnic group.  PPARb6 was
typed using an engineered NdeI enzyme site and the resulting allele frequency for the T
allele was 0.127 for NH and 0.137 for H.  The two sites in PPARγ were each typed by
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restriction enzyme digestion and showed similar frequencies in the Hispanics where
q=0.12 for both sites, but were somewhat different in the Non-Hispanics with the rare
allele at a frequency of 0.12 for PPARg2 and 0.15 for PPARg6.  The variants in RXRβ,
typed by restriction enzyme digestion, showed the highest frequencies of the typed
polymorphisms with the A allele of RXRb10 at q=0.13 in NH and q=0.20 in H while the T
allele of RXRb+140 showed a frequency of 0.27 in NH and 0.30 in H.  Linkage
disequilibrium (D’) was then calculated between each pair of polymorphisms (see Table
12).
Figure 6: Locations of polymorphisms in the PPARs
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Figure 7: Locations of Polymorphisms in RXRβ
Table 10: Allele frequencies for PPAR and RXR polymorphisms in the SLVDS
population
FrequencyPolymorphic
Site
Allele Overall
Frequency Hispanics Non-Hispanics
Method of
Detection
C (Leu) 0.905 0.886 0.918PPARa5
G (Val) 0.095 0.114 0.082
Oligonucleotide
Ligation Assay
T (Val) 0.980 0.965 0.991PPARa6
C (Ala) 0.020 0.035 0.009
Oligonucleotide
Ligation Assay
C 0.869 0.863 0.873PPARb6
T 0.131 0.137 0.127
NdeI Digestion
C (Pro) 0.883 0.884 0.882PPARg2
G (Ala) 0.117 0.116 0.118
BstUI Digestion
C 0.861 0.882 0.848PPARg6
T 0.139 0.118 0.152
NlaIII Digestion
T 0.842 0.800 0.871RXRb10
A 0.158 0.200 0.129
DdeI Digestion
A 0.721 0.704 0.732RXRb+140
T 0.279 0.296 0.268
MboI Digestion
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Table 11: Genotype Frequencies for PPAR and RXR polymorphisms in the SLVDS
population
Hispanics Non-HispanicsPolymorphic
Site 11 12 22 HWE* 11 12 22 HWE*
PPARa5 (C/G) 0.84 0.15 0.01 1.00 0.78 0.22 0.003 0.22
PPARa6 (T/C) 0.98 0.02 0 0.98 0.93 0.07 0 0.81
PPARb6 (C/T) 0.77 0.20 0.03 0.12 0.76 0.21 0.03 0.09
PPARg2 (C/G) 0.78 0.21 0.01 1.00 0.78 0.20 0.01 1.00
PPARg6 (C/T) 0.72 0.25 0.03 0.88 0.77 0.22 0.01 0.86
RXRb10 (T/A) 0.76 0.23 0.01 0.89 0.63 0.33 0.04 0.90
RXRb+140 (A/T) 0.55 0.37 0.08 0.63 0.52 0.36 0.12 0.17
*HWE: p-value from χ2 test of Hardy Weinberg Equilibrium
Table 12: D’ measurements of linkage disequilibrium between typed polymorphisms
PPARa5 PPARa6 PPARb6 PPARg2 PPARg6 RXRb10 RXRb+140
PPARa5 - 0.9633 0.0504 0.0608 0.2063 0.0441 0.1024
PPARa6 0.9633 - 0.1498 0.1357 0.1049 0.0064 0.2023
PPARb6 0.0504 0.1498 - 0.1084 0.2096 0.1076 0.0282
PPARg2 0.0608 0.1357 0.1084 - 0.7670 0.1188 0.0066
PPARg6 0.2063 0.1049 0.2096 0.7670 - 0.1156 0.0261
RXRb10 0.0441 0.0064 0.1076 0.1188 0.1156 - 0.9995
RXRb+140 0.1024 0.2023 0.0282 0.0066 0.0261 0.9995 -
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C. Analysis of Multi-Locus Models
1. Descriptive Statistics
Descriptive statistics were calculated for all variables used in the analysis (see
Appendix C).  The frequencies of the categorical variables were determined and no
significant differences between Hispanics and Non-Hispanics were found for sex or
smoking status using a χ2 test (see Table 13).  The study population consisted of 42%
Hispanic and 58% Non-Hispanic individuals with 47% males and 53% females in the
entire sample.  Only 15%of the subjects reported that they were current smokers while
36% were classified as ex-smokers and 49% as non-smokers.
Table 13: Frequencies of categorical variables in SLVDS population
Catagory Unsplit Non-Hispanics Hispanics
p-value
(NH vs H)
Non-smoker 49.3% 50.9% 47.0%
Current smoker 14.7% 13.0% 17.1%
Smoking
Status
Ex-smoker 36.0% 36.1% 35.9%
0.271
Male 47.2% 48.5% 45.4%Sex
Female 52.8% 51.5% 54.6%
0.398
Non-Hispanic 58.0%Ethnicity
Hispanic 42.0%
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Extreme outliers were identified through examination of the distributions for the
continuous variables.  A total of 17 samples were classified as extreme outliers and
were removed from all subsequent analyses.  In many of the cases, these extreme
values were likely the result of incorrect measurements or data entry errors as they
were biologically implausible.  After removal of the outliers, mean, median, maximum,
minimum, range, standard error of the mean, standard deviation, skewness and kurtosis
were calculated for all of the continuous variables in the entire SLVDS sample as well
as in each ethnic group.  The average age of the study group was 63 years and was
between 34 and 88 years of age.  Fasting glucose, fasting insulin, and HOMA IR had
highly skewed distributions (see Table 14).  When these variables were used as the
outcome of a linear regression analysis, they were transformed using the natural log to
reduce their skewness.
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Table 14: Descriptive statistics for continuous variables in the SLVDS population after
removal of outliers
Variables Mean (SD) Skewness Kurtosis N
BMI (kg/m2) 27.29 (4.86) 0.755 1.402 746
Fat Mass (kg) 26.21 (9.29) 0.457 0.447 697
% Body Fat (%) 35.45 (9.63) -0.110 -0.545 697
Lean Mass (kg) 44.67 (10.83) 0.428 -0.863 697
Fasting FFA (µmol/L) 598 (238) 0.660 0.342 745
Cholesterol (mg/dl) 201 (36) 0.366 0.699 745
Triglycerides (mg/dl) 178 (92) 1.797 4.475 745
Fasting Glucose (mg/dl) 100 (22) 3.663 18.980 745
ln(Fasting Glucose) 4.59 (0.17) 2.091 7.614 745
Fasting Insulin (mg/dl) 11.08 (6.58) 2.021 5.321 745
ln(Fasting Insulin) 2.27 (0.50) 0.494 0.012 745
HOMA IR 17.37 (13.02) 2.445 7.558 745
ln(HOMA IR) 2.66 (0.60) 0.515 0.159 745
Systolic BP (mm) 127 (18) 1.009 1.766 745
Diastolic BP (mm) 74 (9) 0.322 0.770 745
Caloric Intake (cal) 1931 (846) 0.979 1.568 713
Fat Intake (g) 76 (42) 1.278 2.683 712
Physical Activity (kCal/kg/hr) 282.6 (61.9) 1.937 3.940 725
Age (years) 63 (12) -0.176 -0.756 746
Skin Reflectance (%) 32.64 (3.83) -0.402 0.155 744
Analysis of variance was used to test for ethnic differences in the continuous
variables after removal of the outliers (see Table 15).  Hispanic individuals showed
significantly higher values for fasting free fatty acids (H=640, NH=568; p<0.001),
triglycerides (H=190, NH=169; p=0.002), fasting glucose (H=104, NH=98; p<0.001),
fasting insulin (H=12.3, NH=10.2; p<0.001) and HOMA IR (H=19.9, NH=15.5; p<0.001).
In contrast, Non-Hispanic individuals had higher caloric intake (NH=2016, H=1810;
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p=0.001) and fat intake (NH=79, H=71; p=0.015).  Skin reflectance was higher in the
Non-Hispanic subjects as expected (NH=34.3, H=30.4; p<0.001), as was age (NH=64,
H=62; p=0.047).
Table 15: Comparison of mean values (SD) for continuous variables in the SLVDS
population split by ethnicity after removal of outliers
Non-Hispanics Hispanics
Variables
Mean (SD) N Mean (SD) N
p-value
BMI (kg/m2) 27.12 (4.76) 433 27.53 (5.00) 313 0.257
Fat Mass (kg) 26.56 (9.16) 407 25.71 (9.46) 290 0.238
% Body Fat (%) 34.92 (9.40) 407 36.20 (9.92) 290 0.084
Lean Mass (kg) 46.48 (11.36) 407 42.12 (9.52) 290 <0.001
Fasting FFA (µmol/L) 568 (223) 432 640 (252) 313 <0.001
Cholesterol (mg/dl) 201±37 432 200 (35) 313 0.868
Triglycerides (mg/dl) 169 (87) 432 190 (97) 313 0.002
ln(Triglycerides) 5.02 (0.45) 432 5.14 (0.46) 313 0.002
Fasting Glucose (mg/dl) 98 (19) 432 104 (26) 313 <0.001
ln(Fasting Glucose) 4.57 (0.16) 432 4.62 (0.20) 313 <0.001
Fasting Insulin (mg/dl) 10.21 (5.91) 432 12.27 (7.25) 313 <0.001
ln(Fasting Insulin) 2.20 (0.48) 432 2.37 (0.51) 313 <0.001
HOMA IR 15.54 (11.30) 432 19.90 (14.73) 313 <0.001
ln(HOMA IR) 2.57 (0.57) 432 2.78 (0.62) 313 <0.001
Systolic BP (mm) 127 (17) 433 126 (19) 312 0.979
Diastolic BP (mm) 74 (9) 433 74 (9) 312 0.831
Caloric Intake (cal) 2016 (826) 421 1810 (862) 292 0.001
Fat Intake (g) 79 (41) 421 71 (43) 291 0.015
Physical Activity (kCal/kg/hr) 283.7 (61.2) 425 281.1 (63.0) 300 0.517
Age (years) 64 (11) 433 62 (12) 313 0.047
Skin Reflectance (%) 34.25 (2.98) 431 30.42 (3.76) 313 <0.001
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2. Univariate Analysis of Outcome and Predictor Variables
Univariate analyses were carried out to compare all outcome variables with the
predictor variables.  Analysis of variance was used to test for associations between the
outcomes and the categorical variables (including genotype) while linear regression was
used for the continuous variables.  The genotypic means for each of the outcome
variables are given in Tables 16 through 22.  There were no significant associations
between any of the polymorphisms and BMI or fat mass although FFA and PPARb6
were associated in the entire sample as well as in the Hispanic sub-group (see Table
18).  The CC genotype of PPARb6 was 107µmol/L higher than the TT genotype in the
unsplit sample (CC=608, CT=555, TT=497; p=0.011).  Even more strikingly, there was a
difference of 185µmol/L between the two homozygotes in the Hispanics (CC=660,
CT=558, TT=471; p=0.003).  This effect appeared to be additive in both cases with the
T allele lowering FFA by ~56µmol/L and ~92µmol/L in the unsplit sample and Hispanic
sub-sample, respectively.  The Non-Hispanic individuals showed a similar decrease in
FFA although the difference between the homozygous groups was only 54µmol/L and
was not significant (CC=569, CT=551, TT=515; p=0.624).
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Table 16: Means for PPARa5 Genotypes vs. Selected Variables in the SLVDS
Unsplit SLVDS Hispanics Non-Hispanics
PPARa5
11 12 22 11 12 22 11 12 22
BMI
(kg/m2) 27.4 26.8 27.3 27.7 27.0 21.7 27.2 26.6 29.1
FM
(kg)
26.2 26.0 28.2 25.8 25.7 21.0 26.6 26.4 30.6
FFA
(µmol/L) 595 607 780 640 638 732 565 574 797
FG
(mg/dl) 100 101 94 104 103 83 98 99 97
Chol
(mg/dl) 201 198 203 199 205 152 203 191 221
N 607 134 4 243 69 1 364 65 3
* Values in bold show significantly different means between the two genotype groups
(11 vs. 12+22; p<0.05).
* Abbreviations: BMI=body mass index; FM=fat mass; FFA=fasting free fatty acids;
FG=fasting glucose; Chol=total cholesterol
Table 17: Means for PPARa6 Genotypes vs. Selected Variables in the SLVDS
Unsplit SLVDS Hispanics Non-Hispanics
PPARa6
11 12 11 12 11 12
BMI
(kg/m2) 27.2 28.3 27.5 28.4 27.1 28.1
FM
(kg)
26.2 28.3 25.6 28.0 26.5 28.8
FFA
(µmol/L) 597 566 641 593 567 500
FG
(mg/dl) 100 107 104 103 97 119
Chol
(mg/dl) 201 192 201 185 201 211
N 700 28 283 20 417 8
* Values in bold show significantly different means between the two genotype groups
(11 vs. 12; p<0.05).
* Abbreviations: BMI=body mass index; FM=fat mass; FFA=fasting free fatty acids;
FG=fasting glucose; Chol=total cholesterol
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Table 18: Means for PPARb6 Genotypes vs. Selected Variables in the SLVDS
Unsplit SLVDS Hispanics Non-Hispanics
PPARb6
11 12 22 11 12 22 11 12 22
BMI
(kg/m2) 27.4 27.3 25.6 27.7 27.8 24.5 27.3 27.0 26.4
FM
(kg)
26.4 26.6 23.1 25.9 26.2 22.2 26.7 26.9 23.7
FFA
(µmol/L) 608 555 497 660 558 471 569 551 515
FG
(mg/dl) 102 97 91 105 100 92 99 95 90
Chol
(mg/dl) 201 197 205 202 195 186 201 198 218
N 525 139 19 222 60 8 303 79 11
* Values in bold show significantly different means between the three genotype groups
(p<0.05) while values that are underlined show significantly different means only when
two genotype groups are tested (11 vs. 12+22; p<0.05)
* Abbreviations: BMI=body mass index; FM=fat mass; FFA=fasting free fatty acids;
FG=fasting glucose; Chol=total cholesterol
Table 19: Means for PPARg2 Genotypes vs. Selected Variables in the SLVDS
Unsplit SLVDS Hispanics Non-Hispanics
PPARg2
11 12 22 11 12 22 11 12 22
BMI
(kg/m2) 27.4 27.3 27.1 27.4 28.0 27.4 27.3 28.0 27.4
FM
(kg)
26.1 26.7 27.8 27.3 26.8 26.9 26.8 26.2 30.0
FFA
(µmol/L) 591 608 534 625 674 683 566 563 415
FG
(mg/dl) 101 101 105 104 103 127 98 99 88
Chol
(mg/dl) 201 198 216 201 196 199 201 199 229
N 540 141 9 225 57 4 315 84 5
* Abbreviations: BMI=body mass index; FM=fat mass; FFA=fasting free fatty acids;
FG=fasting glucose; Chol=total cholesterol
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Table 20: Means for PPARg6 Genotypes vs. Selected Variables in the SLVDS
Unsplit SLVDS Hispanics Non-Hispanics
PPARg6
11 12 22 11 12 22 11 12 22
BMI
(kg/m2) 27.5 27.0 26.6 27.5 27.7 27.9 27.4 26.7 26.1
FM
(kg)
26.4 26.0 25.6 25.6 26.6 27.0 27.1 25.6 25.1
FFA
(µmol/L) 593 594 580 620 689 670 573 540 552
FG
(mg/dl) 101 100 94 104 103 96 98 97 94
Chol
(mg/dl) 201 201 201 201 196 188 201 204 205
N 511 159 13 215 58 3 296 101 10
* Abbreviations: BMI=body mass index; FM=fat mass; FFA=fasting free fatty acids;
FG=fasting glucose; Chol=total cholesterol
Table 21: Means for RXRb10 Genotypes vs. Selected Variables in the SLVDS
Unsplit SLVDS Hispanics Non-Hispanics
RXRb10
11 12 22 11 12 22 11 12 22
BMI
(kg/m2) 27.3 27.5 29.0 27.7 27.5 28.0 27.1 27.4 30.7
FM
(kg)
26.4 26.1 24.8 25.7 25.7 24.8 26.8 26.5 24.8
FFA
(µmol/L) 588 616 646 637 647 710 561 584 530
FG
(mg/dl) 101 100 100 105 103 98 99 97 104
Chol
(mg/dl) 200 202 203 200 198 195 200 205 219
N 427 163 14 154 82 9 273 81 5
* Abbreviations: BMI=body mass index; FM=fat mass; FFA=fasting free fatty acids;
FG=fasting glucose; Chol=total cholesterol
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Table 22: Means for RXRb+140 Genotypes vs. Selected Variables in the SLVDS
Unsplit SLVDS Hispanics Non-Hispanics
RXRb+140
11 12 22 11 12 22 11 12 22
BMI
(kg/m2) 27.3 27.2 27.7 27.6 27.2 28.5 27.1 27.3 25.8
FM
(kg)
25.9 26.8 24.9 25.7 25.7 23.8 26.0 27.5 25.8
FFA
(µmol/L) 588 605 582 622 667 609 563 567 559
FG
(mg/dl) 100 102 99 102 108 98 98 99 100
Chol
(mg/dl) 198 203 203 193 208 202 201 200 203
N 333 218 55 138 84 25 195 134 30
* Values in bold show significantly different means between the three genotype groups
(p<0.05).
* Abbreviations: BMI=body mass index; FM=fat mass; FFA=fasting free fatty acids;
FG=fasting glucose; Chol=total cholesterol
Correlations among predictor variables were also tested to determine co-linearity
(see Appendix D).  Bivariate correlations were calculated for each pair of continuous
variables and the Χ2 test was used for each pair of categorical variables including the
genotype data.  In the case of the genotype data, the Χ2 test approximates a test for
linkage disequilibrium (Schneider, 1995).  One-way ANOVA was used to test for
associations between categorical and continuous variables.  Sex was found to be an
important predictor for all of the outcome variables except BMI (see Table 23).
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Table 23: Mean values (SD) for outcome variables in males and females
Males Females
Outcomes Mean (SD) N Mean (SD) N p-value
BMI (kg/m2) 27.3 (4.1) 352 27.3 (5.4) 394 0.893
FM (kg) 23.2 (7.6) 330 28.9 (9.8) 367 <0.001
FFA (µmol/L) 523 (211) 351 665 (241) 394 <0.001
FG (mg/dL) 104 (24) 351 97 (19) 394 <0.001
Chol (mg/dL) 195 (36) 351 206 (36) 394 <0.001
* Abbreviations: BMI=body mass index; FM=fat mass; FFA=fasting free fatty acids;
FG=fasting glucose; Chol=total cholesterol
Analysis of variance was used to look for correlations between the genotype
variables and the continuous predictor variables.  This resulted in several significant
results.  First, in the Non-Hispanic group, when the PPARa5 GG individuals were
combined with the heterozygous subjects they showed significantly lower cholesterol
levels compared to the CC homozygotes (CC=203, CT+TT=192; p=0.036) (see Table
16).  The Non-Hispanics also showed a significant increase of 22mg/dL for fasting
glucose levels when they were heterozygous for PPARa6 (TT=97, TC=119; p<0.001)
(Table 17).  Neither of these effects was seen in the Hispanics.  On the other hand,
heterozygosity for PPARa6 was significantly associated with lower cholesterol levels in
Hispanics (TT=201, TC=185; 0.045), but not in the Non-Hispanic individuals (see Table
17).  In addition to FFA, PPARb6 was also associated with fasting glucose levels.  This
effect was significant in the unsplit sample where the CC homozygotes showed an
increase of 11mg/dL over the TT homozygotes (CC=102, CT=97, TT=91; p=0.013).  In
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the ethnic sub-groups, the trend remained although it was not significant (NH: CC=99,
CT=95, TT=90; p=0.075; H: CC=105, CT=100, TT=92; p=0.138) (see Table 18).
Presence of the T allele for the RXRb+140 polymorphism was associated with
significantly higher cholesterol levels in the Hispanics (AA=193, AT=208, TT=202;
p=0.007), but no effect was seen in the Non-Hispanics (see Table 22).  The PPARg2,
PPARg6 and RXRb10d polymorphisms were not associated with any of the continuous
predictor variables (see Table 19, Table 20, and Table 21).  Due to the fact that two of
the original outcomes (BMI and FM) did not appear to be related to any of these
polymorphisms in our data set, they were excluded from subsequent analyses while
fasting glucose and cholesterol were added as new outcome variables.
3. Univariate Analysis for New Outcome Variables
In addition to the analysis of variance results shown above, each of the new
outcome variables was tested for associations with the genotypic data in the four ethnic/
gender sub-groups: NH males, NH females, H males and H females.  The PPARb6
variant was again related to FFA in Hispanics, but only in the females (CC=728,
CT+TT=584; p=0.003).  Both groups of females also showed a significant association
between PPARg6 and FFA, although in different directions, with the Non-Hispanic
females showing a decrease of 81µmol/L in the presence of the T allele (NH: CC=651,
CT+TT=580; p=0.049) while the T allele increased FFA in Hispanic females by
114µmol/L (H: CC=675, CT+TT=789; p=0.021).  Fasting glucose levels were associated
with PPARa6 (TT=100, TC=128; p<0.001) and PPARb6d (CC=103, CT+TT=96;
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p=0.045) in the Non-Hispanic males and RXRb+140 (AA=104, AT=118, TT=103;
p=0.045) in the Hispanic male group.  The Hispanic males also showed an association
between RXRb+140 and cholesterol levels with presence of the T allele increasing
cholesterol levels by ~20mg/dL (AA=186, AT=204, TT=206; p=0.013).
Associations between all pair-wise combinations of the polymorphisms and each of
the outcome variables were tested by two-way ANOVA and several significant
interactions were found (p<0.05).  In Non-Hispanics, two interactions
(PPARa5d*PPARb6d and RXRb10d*RXRb+140d) were associated with FFA.  The
PPARa5d*PPARb6d interaction was also significantly associated with FFA in the Non-
Hispanic Males.  Fasting glucose was associated with the greatest number of
interactions with two terms in the unsplit group (PPARa6*PPARg2d and
PPARa6*PPARg6d), three terms in the Non-Hispanics (PPARa6*PPARg2d,
PPARa6*PPARg6d and PPARa6*RXRb+140), two terms in the Hispanic group
(PPARa5d*PPARg2d and RXRb10d*RXRb+140d), one term for Non-Hispanic females
(PPARa5d*RXRb+140d) and two terms in the Hispanic males (PPARa5d*PPARg2d and
PPARg2d*PPARg6d).  Cholesterol also showed significant associations with the
PPARa5d*PPARb6d interaction (in Hispanics and Hispanic Females) and
PPARa5d*RXRb10d (in Non-Hispanic Females).  These terms, other interactions with a
p-value less than 0.20 and the significant terms from the single locus analysis were
considered potentially interesting for the regression analysis and were used to build the
regression models that were initially tested (see Table 24, Table 25, and Table 26).
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Table 24: List of interesting terms used to build regression models for fasting free fatty
acids.
FFA Unsplit
PPARb6
PPARa5d*PPARb6d
PPARb6*RXRb+140d
PPARg6d*RXRb+140d
RXRb10d*RXRb+140d
Non-Hispanics Hispanics
PPARa5d*PPARb6d
PPARa5d*PPARg6d
PPARa5d*RXRb+140d
PPARa6*PPARg2d
PPARb6d*RXRb10d
RXRb10d*RXRb+140
PPARb6d
PPARa6*PPARg6d
Non-Hispanic Males Non-Hispanic Females
Hispanic
Males Hispanic Females
PPARa5d*PPARb6d
PPARg2d*PPARg6d
RXRb10d*RXRb+140d
PPARg6d
PPARa5d*PPARb6d
PPARa5d*RXRb+140d
RXRb10d*RXRb+140d
No
terms
PPARb6d
PPARg6d
PPARa5d*RXRb+140d
*Terms in bold are significantly associated with the outcome variable (p<0.05)
*Interesting terms were defined as having either a one-way ANOVA result with p<0.05
or a two-way ANOVA interaction with p<0.20.
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Table 25: List of interesting terms used to build regression models for fasting glucose
FG Unsplit
PPARb6
PPARa5d*PPARa6
PPARa5d*PPARg2d
PPARa6*PPARg2d
PPARa6*PPARg6d
PPARa6*RXRb+140
PPARg2d*PPARg6d
RXRb10d*RXRb+140
Non-Hispanics Hispanics
PPARa6
PPARb6d
PPARa6*PPARb6d
PPARa6*PPARg2d
PPARa6*PPARg6d
PPARa6*RXRb+140
PPARa5d*PPARg2d
PPARg2d*PPARg6d
RXRb10d*RXRb+140d
Non-Hispanic
Males Non-Hispanic Females Hispanic Males Hispanic Females
PPARa6
PPARb6d
PPARa5d*PPARg2d
PPARa5d*RXRb+140d
PPARb6d*PPARg6d
RXRb+140
PPARa5d*PPARg2d
PPARb6d*RXRb10d
PPARg2d*PPARg6d
PPARg2d*PPARb6d
*Terms in bold are significantly associated with the outcome variable (p<0.05)
*Interesting terms were defined as having either a one-way ANOVA result with p<0.05
or a two-way ANOVA interaction with p<0.20.
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Table 26: List of interesting terms used to build regression models for total cholesterol
Chol Unsplit
PPARa6*PPARb6d
PPARg2d*PPARg6d
Non-Hispanics Hispanics
PPARa5d
PPARa5d*RXRb10d
PPARa6*PPARg6d
PPARg6d*RXRb10d
PPARa6
RXRb+140
PPARa5d*PPARb6d
PPARa5d*RXRb+140d
PPARg2d*PPARg6d
Non-Hispanic Males Non-Hispanic
Females Hispanic Males Hispanic Females
PPARb6d*RXRb10d
PPARg6d*RXRb10d
RXRb10d*RXRb+140d
PPARa5d*RXRb10d
RXRb10d*RXRb+140d
RXRb+140
PPARa5d*PPARb6d
PPARa5d*RXRb+140d
PPARa6
PPARa5d*PPARb6d
PPARb6d*PPARg2d
PPARb6d*PPARg6d
PPARg2d*PPARg6d
PPARg6d*RXRb10d
*Terms in bold are significantly associated with the outcome variable (p<0.05)
*Interesting terms were defined as having either a one-way ANOVA result with p<0.05
or a two-way ANOVA interaction with p<0.20.
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4. Regression Modeling
Regression models were built to test the polymorphisms that were found to be
potentially interesting in the analysis described above.  Final models were constructed
for each outcome in all seven of the groups (see Table 27, Table 28, Table 29 and
Appendix E).  Most of the models were reduced to one or two significant terms, either
single locus effects or interactions, which explained between 1% and 4% of the variation
in the unadjusted outcome variables.  For example, the final model for fasting glucose in
the Non-Hispanic females showed that the PPARb6d*PPARg6d interaction was the only
significant predictor (p=0.008) and explained 3.5% of the trait variation (see Table 30).
Therefore, the double common homozygotes (CC/CC) are expected to have a mean FG
of 96.32mg/dL compared to 90.92mg/dL for all other genotypes combinations (see
Figure 8).
Table 27: Regression Model Summaries for Fasting Free Fatty Acids (µmol/L) vs.
PPARs and RXRs
Group Terms r2 p-value
Unsplit PPARb6 0.013 0.011
Non-Hispanics
RXRb+140
RXRb10*RXRb+140 0.016 0.061
Hispanics
PPARb6
PPARa6*PPARg6
0.052 0.001
Non-Hispanic Males* PPARa5*PPARb6 0.018 0.066
Non-Hispanic Females No Model N/A N/A
Hispanic Males No Model N/A N/A
Hispanic Females
PPARb6
PPARa5*RXRb+140
0.110 P=0.001
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Table 28: Regression Model Summaries for Fasting Glucose (mg/dL) vs. PPARs and
RXRs
Group Terms r2 p-value
Unsplit
PPARa6
PPARb6
PPARg6
PPARa6*PPARg6
0.026 0.002
Non-Hispanics
PPARa6
PPARa6*PPARb6 0.030 0.003
Hispanics RXRb10*RXRb+140 0.017 0.024
Non-Hispanic Males PPARb6 0.027 0.024
Non-Hispanic Females PPARb6*PPARg6 0.035 0.008
Hispanic Males
PPARg6
PPARa5*hPPARg2
PPARa5*PPARg6
PPARg2*PPARg6
PPARg2*RXRb+140
PPARg6*RXRb+140
0.170 0.002
Hispanic Females No Model N/A N/A
Table 29: Regression Model Summaries for Cholesterol (mg/dL) vs. PPARs and RXRs
Group Terms r2 p-value
Unsplit No Model N/A N/A
Non-Hispanics PPARa5d*PPARa6 0.012 0.022
Hispanics PPARa6*RXRb+140 0.040 0.002
Non-Hispanic Males No Model N/A N/A
Non-Hispanic Females RXRb10*RXRb+140 0.026 0.034
Hispanic Males RXRb+140 0.071 0.003
Hispanic Females
PPARg2
PPARa6*RXRb10
PPARg2*PPARg6
PPARg6*RXRb10
0.108 0.009
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Table 30: Regression Model for ln(Fasting Glucose) in Non-Hispanic Females
Term β p-value
Constant 4.510 0.000
PPARb6d*PPARg6d 0.0577 0.008
r2=0.035
p-value=0.008
Figure 8: PPARb6d*PPARg6d vs. Fasting Glucose in Non-Hispanic Females
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There were, however, several models that accounted for an even higher
percentage of variation in the outcomes.  The highest r2 value was achieved in the
fasting glucose model for Hispanic males that explained 17% of the variation and
included six predictors (see Table 31).  The significant terms consisted of a single locus
effect by PPARg6d and various interactions between PPARa5d, PPARg2d, PPARg6d
and RXRb+140d.  The final model for cholesterol in Hispanic males included only
RXRb+140d as a significant predictor, yet accounts for over 7% of the trait variation
(r2=0.071, p=0.003).  This model predicts that presence of the T allele increases total
cholesterol levels by 18.7mg/dL over the AA individuals (see Table 32 and Figure 9).
Another final model that was constructed for Hispanic females was able to explain 11%
of the variation in fasting free fatty acids with PPARb6d andPPARa5d*RXRb+140d as
predictors (p=0.001) (see Table 33).  In this model, subjects homozygous for the
PPARb6 C allele show an increase of 156µmol/L for FFA versus individuals who have
at least one of the rare alleles at each of the three sites (-T/-G/-T for b6/a5/b140) while
those who are homozygous for the common allele of both PPARa5d and RXRb+140d
have FFA levels 109µmol/L below the rare allele carriers.  Individuals homozygous for
the common alleles at each of the three sites show FFA levels slightly above the rare
allele carriers (+47µmol/L) (see Figure 10).
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Table 31: Regression Model for ln(Fasting Glucose) in Hispanic Males
Term β p-value
Constant 4.630 0.000
PPARg6d 0.677 <0.001
PPARa5d*PPARg2d 0.670 <0.001
PPARa5d*PPARg6d -0.646 <0.001
PPARg2d*PPARg6d -0.646 <0.001
PPARg2d*RXRb+140d -0.754 <0.001
PPARg6d*RXRb+140d -0.711 0.001
r2=0.170
p-value=0.002
Table 32: Regression Model for Cholesterol in Hispanic Males
Term β p-value
Constant 204.596 0.000
RXRb+140d -18.659 0.003
r2=0.071
p-value=0.003
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Figure 9: RXRb+140 vs. Cholesterol in Hispanic Males
Table 33: Regression Model for Fasting Free Fatty Acids in Hispanic Females
Term β p-value
Constant 632.443 0.000
PPARb6d 156.324 0.005
PPARa5d*RXRb+140d -109.391 0.014
r2=0.110
p-value=0.001
85
Figure 10: Multi-Locus Genotype Means for PPARb6d/PPARa5d/RXRb+140d vs
Fasting Free Fatty Acids in Hispanic Females
5. Combined Analysis with UCPs and FABPs
Because of the known relationships between the PPARs, RXRs, UCPs, and
FABPs, regression models were constructed using polymorphisms from all of these
gene families.  Regression models, similar to those described above, were constructed
based on genotypic data for twenty polymorphisms in the UCP and FABP genes,
provided by Coleen Damcott (Damcott, 2002).  The allele frequencies of these sites are
reported in Table 34.  Several of these polymorphisms are in high linkage
disequilibrium; therefore, many of the sites were not used in the analysis.  Five
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variations in the FABP2 promoter in complete linkage disequilibrium were represented
in the analysis as FABP2pID, with the I allele referring to the more common G/G/D/I/I
haplotype.  The other sites used to represent another related variation were UCP1-2 for
UCP1-5, UCP3p-55 for UCP3-3a, FABP2p-834 for FABP2-2, and FABP4p-376 for
FABP4-2a.  In addition to these five polymorphisms and the seven previously discussed
PPAR or RXR variants, six other sites (UCP2-4, UCP2-8, UCP3-5, FABP4-2b,
FABP3pID and FABP3p-313) were considered when building the combined regression
models (see Figure 11 and Figure 12).  Six of the UCP or FABP sites (UCP2-4, UCP2-
8, UCP3-5, FABP2pID, FABP2p-834, and FABP3pID) were found to be at a high
enough frequency for all three genotypes to be considered separately in the regression
models so two dummy variables were created according to the criteria previously
described (see Section III.D.1).
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Table 34:  Allele frequencies for Polymorphisms in the UCPs and FABPS
FrequencyPolymorphic
Site
Allele Overall
Frequency Hispanics Non-Hispanics
Method of
Detection
G (Ala) 0.900 0.883 0.911UCP1 Exon 2
A (Thr) 0.100 0.117 0.089
HhaI Digestion
A (Met) 0.899 0.888 0.911UCP1 Exon 5
T (Leu) 0.101 0.112 0.089
HindIII Digest
C (Ala) 0.547 0.537 0.553UCP2 Exon 4
T (Val) 0.453 0.463 0.447
EaeI Digestion
Del 0.665 0.679 0.656UCP2 Exon 8
Ins 0.335 0.321 0.345
2% Agarose Gel
(45bp InsDel)
T 0.747 0.768 0.731UCP3 Exon 3a
C 0.235 0.232 0.269
DrdI Digestion
G (Val) 0.995 0.992 0.998UCP3 Exon 3b
A (Ile) 0.005 0.008 0.002
AspI Digestion
T 0.545 0.557 0.536UCP3 Exon 5
C 0.455 0.443 0.464
RsaI Digestion
G (Ala) 0.715 0.690 0.733FABP2 Exon 2
A (Thr) 0.285 0.310 0.267
HhaI Digestion
T 0.857 0.909 0.819FABP4 Intron 2a
G 0.143 0.091 0.181
AflIII Digestion
Ins 0.879 0.837 0.908FABP4 Intron 2b
Del 0.121 0.163 0.092
PvuII Digestion
C 0.782 0.805 0.765UCP3 Promoter
(-55bp) T 0.218 0.195 0.235
AvaI Digestion
C 0.709 0.684 0.727FABP2 Promoter
(-834bp) T 0.291 0.316 0.273
BanII Digestion
G 0.592 0.607 0.581FABP2 Promoter
(-778bp) T 0.408 0.393 0.419
G 0.592 0.607 0.581FABP2 Promoter
(-260bp) A 0.408 0.393 0.419
Del 0.592 0.607 0.581FABP2 Promoter
(-169bp) Ins 0.408 0.393 0.419
Ins 0.592 0.607 0.581FABP2 Promoter
(-166bp) Del 0.408 0.393 0.419
Ins 0.592 0.607 0.581FABP2 Promoter
(-136bp) Del 0.408 0.393 0.419
3% Agarose
Gel: 7bp overall
size difference
in Ins/Del
polymorphisms.
Other
genotypes
inferred based
on linkage
disequilibrium.
Del 0.586 0.565 0.600FABP3 Promoter
(-493bp) Ins 0.414 0.435 0.400
Direct
Sequencing
C 0.771 0.742 0.790FABP3 Promoter
(-313bp) T 0.229 0.258 0.210
Direct
Sequencing
A 0.856 0.894 0.829FABP4 Promoter
(-376bp) C 0.144 0.106 0.171
Fluorescence
Polarization
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Figure 11: Locations of Polymorphisms in the FABPs
Figure 12: Locations of Polymorphisms in the UCPs
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Regression models were constructed to predict fasting free fatty acids and
cholesterol in each of the four ethnic/sex groups. The r2 values for the eight models
ranged from 0.054 up to 0.234 and most only contained two or three terms (see Table
35, Table 36 and Appendix G).  All of these final models, except the Non-Hispanic
female model for cholesterol, were able to explain a greater amount of the trait variation
than the sum of the two corresponding models from the PPAR/RXR and UCP/FABP
analyses.  For example, the fasting free fatty acids model in Non-Hispanic females from
the UCP/FABP analysis showed that the UCP2-4*UCP3-5 interaction was the only
significant predictor of FFA levels with an r2 value of 0.058 (see Appendix F, Table 68).
The PPAR/RXR analysis did not predict any of the polymorphisms to be associated with
fasting free fatty acids levels in Non-Hispanic females (see Table 27).  However, when
all eighteen of the sites are considered together, interactions between four of these sites
(PPARa5d, PPARg6d, UCP3-5 and FABP3pID) are able to account for almost 14% of
the variation in FFA levels (see Table 35).
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Table 35: Combined Regression Model Summaries for Fasting Free Fatty Acids
(µmol/L)
Group Terms r2 p-value
Non-Hispanic Males*
PPARa5d*PPARb6d
PPARb6d*FABP3pID 0.054 0.018
Non-Hispanic
Females
PPARg6d
PPARa5d*FABP3pID
PPARg6d*UCP3-5
PPARg6d*FABP3pID
0.139 <0.001
Hispanic Males
UCP2-4
UCP2-8
0.101 0.008
Hispanic Females
UCP1-2
FABP3pID
UCP1-2*RXRb+140d
UCP1-2*UCP3p-55
UCP1-2*FABP3pID
UCP3p-55*PPARb6
0.234 <0.001
*r2 is in bold if it is more than the sum of the corresponding models from the PPAR/RXR
and UCP/FABP analyses
Table 36: Combined Regression Model Summaries for Cholesterol (mg/dL)
Group Terms r2 p-value
Non-Hispanic Males
PPARb6d
PPARg6d
PPARg6d*RXRb10d
PPARb6d*UCP1-2
PPARg6d*FABP2p-834
RXRb10d*UCP1-2
0.094 0.025
Non-Hispanic
Females
FABP2pID
PPARa5d*UCP3-5
0.064 0.009
Hispanic Males
RXRb+140
UCP1-2
UCP1-2*UCP2-8
0.197 >0.001
Hispanic Females
UCP2-8
UCP3-5*FABP3pID
PPARg6*UCP2-8
0.157 0.002
*r2 is in bold if it is more than the sum of the corresponding models from the PPAR/RXR
and UCP/FABP analyses
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The final model for cholesterol in Hispanic males accounted for almost 20% of
the variation in unadjusted total cholesterol levels (r2=0.197) and included RXRb+140d,
UCP1-2d and UCP1-2d*UCP2-8 as significant predictors (p<0.001) (see Table 37).  The
T allele of RXRb+140d was again shown to increase cholesterol levels by ~22mg/dL
compared to AA homozygotes and presence of the A allele for UCP1-2 decreased
cholesterol levels by 47mg/dL versus the GG individuals.  However, the UCP1-2 GG
individuals showed a modified effect when combined with the UCP2-8 Del allele which
lowered cholesterol levels by ~55mg/dL (see Figure 13).  Therefore, the subjects with a
multi-locus genotype of GG/II/-T for UCP1-2/UCP2-8/RXRb+140 were predicted to have
the highest mean cholesterol levels of 257mg/dL by this model.
Table 37: Combined Regression Model for Cholesterol in Hispanic Males
Term β p-value
Constant 204.596 0.000
RXRb+140d -22.228 <0.001
UCP1-2d 47.337 0.002
UCP1-2d*UCP2-8v1 -52.358 <0.001
UCP1-2d*UCP2-8v2 -57.761 <0.001
r2=0.197
p-value<0.001
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Figure 13: UCP1-2 genotype modification by UCP2-8 for cholesterol in Hispanic Males
The final model constructed for fasting free fatty acids in Hispanic females was
able to account for 23.4% of the trait variation (see Table 38).  This model included six
terms with UCP1-2d showing the greatest effect on FFA levels where the GG
homozygotes were predicted to have cholesterol levels elevated by 315µmol/L.  This
effect, however, was highly modified by three other polymorphisms so that in individuals
homozygous for the common alleles at RXRb+140, UCP3p-55 and FABP3pID, the
UCP1-2 GG genotype was predicted to have an FFA level of 554µmol/L while presence
of the UCP1-2 A allele would increase this to 913µmol/L.  In addition, individuals who
were homozygous for the common alleles of UCP3p-55 and PPARb6 also were
predicted to have 132µmol/L higher free fatty acid levels.  Therefore, GG/DD/AA/CC/-T
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(UCP1-2/FABP3pID/RXRb+140/UCP3p-55/PPARb6) was the multi-locus genotype with
the lowest predicted mean FFA levels of 422µmol/L while –A/ DD/AA/CC/CC was the
genotype with the highest predicted value of 913µmol/L (see Figure 14 and Figure 15).
Table 38: Combined Regression Model for Fasting Free Fatty Acids (µmol/L) in
Hispanic Females
Term β p-value
Constant 557.985 0.000
UCP1-2d 315.908 <0.001
FABP3pIDv2 223.693 0.003
UCP1-2d*RXRb+140d -168.160 0.001
UCP1-2d*UCP3p-55d -182.675 0.006
UCP1-2d*FABP3pIDv2 -324.455 <0.001
UCP3p-55d*PPARb6d 131.697 0.018
r2=0.234
p-value<0.001
94
Figure 14: UCP1-2d vs fasting free fatty acid levels in Hispanic Females
Figure 15: FABP3pID, UCP3p-55d and RXRb+140d modification of UCP1-2 GG
Hispanic Females for fasting free fatty acid levels
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6. Tissue Specific Analysis
Regression models were next tested that contained polymorphisms in the gene
isoforms with the highest level of expression in several different tissues.  Muscle models
included sites in PPARα, FABP3 and UCP3.  Adipose models looked at PPARγ,
FABP4, UCP1 and UCP2 variations.  Intestinal models tested PPARβ, FABP2 and
UCP2 polymorphisms.  After adjustment for several covariates, final models for fat mass
and lean mass were found in both males and females (see Table 39, Table40, Table41
and Table 42).  Similar models were also constructed for several lipid measures, but are
not presented here in detail (Damcott, 2002) (see Appendix H).  Two of the muscle
models (FM in females and LM in males) showed only one significant interaction term
while no terms were kept for the other two models (FM in males and LM in females).
The adipose models were somewhat more complex yet still did not explain much of the
trait variation; the exception was the female model for lean mass that had an r2 of 0.056.
On the other hand, the intestinal models accounted for the highest portion of the
variation in lean mass for both sexes and in fat mass for males.
96
Table 39: Fat Mass Tissue Specific Regression Model Summary for Males
Tissue Genotype Terms p-value r2
Muscle No Model N/A N/A
Adipose
PPARg2*FABP4-2b
UCP1-2*FABP4-2b 0.017 0.027
Intestine
UCP2-8*FABP2p-ID
UCP2-8*FABP2p-834
FABP2p-ID*FABP2p-834
0.003 0.057
Overall
UCP2-8
PPARg2*FABP4-2b
UCP1-2*FABP4-2b
UCP2-8*FABP2p-ID
UCP2-8*FABP2p-834
<0.001 0.095
Table 40: Fat Mass Tissue Specific Regression Model Summary for Females
Tissue Genotype Terms p-value r2
Muscle UCP3-5*FABP3p-313 0.001 0.033
Adipose No Model N/A N/A
Intestine No Model N/A N/A
Overall UCP3-5*FABP3p-313 0.001 0.033
97
Table 41: Lean Mass Tissue Specific Regression Model Summary for Males
Tissue Genotype Terms p-value r2
Muscle PPARa5*UCP3-5 0.025 0.016
Adipose UCP2-4*FABP4-2b 0.033 0.015
Intestine
PPARb6*UCP2-4
UCP2-4*FABP2p-834
UCP2-8*FABP2p-834
0.002 0.058
Overall
PPARb6*UCP2-4
UCP2-4*FABP4-2b
UCP2-4*FABP2p-834
UCP2-8*FABP2p-834
0.001 0.074
Table 42: Lean Mass Tissue Specific Regression Model Summary for Females
Tissue Genotype Terms p-value r2
Muscle No Model N/A N/A
Adipose
FABP4p-376
UCP1-2*UCP2-8
UCP1-2*FABP4p-376
UCP2-4*UCP2-8
0.003 0.056
Intestine
UCP2-4
UCP2-8
PPARb6*UCP2-8
UCP2-4*FABP2p-834
<0.001 0.085
Overall
UCP2-4
FABP2p-834
FABP4p-376
PPARb6*UCP2-8
UCP1-2*UCP2-8
UCP1-2*FABP4p-376
UCP2-4*UCP2-8
UCP2-4*FABP2p-834
<0.001 0.155
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Overall tissue models were then tested to determine which tissue was the most
important contributor to fat mass or lean mass variation.  The muscle model in females
was the only tissue with a final model so it was considered the overall final model as
well.  This model showed that individuals homozygous for the common alleles of UCP3-
5 and FABP3p-313 had a 4kg increase in fat mass over the other genotype groups
(r2=0.033, p=0.001) (see Table 43).  The male overall model for fat mass, on the hand,
was a combination of the adipose and intestinal models yet was able to account for
more of the variation in fat mass than the other two models separately (see Table 44).
The adipose contribution consisted of interactions between three polymorphisms,
FABP4-2bd, PPARg2d and UCP1-2d.  In the individuals homozygous for the FABP4-2b
insertion allele, homozygosity for the common allele of PPARg2d and UCP1-2d seem to
compensate for one another.  However, in the FABP4-2b deletion carriers, presence of
the less common alleles for either PPARg2d or UCP1-2d increases fat mass in an
additive manner (see Figure 16).  Homozygosity for the D allele of UCP2-8 was found to
decrease fat mass by ~4kg although this effect was highly modified by the intestinal
FABP2 polymorphisms.  FABP2pID and FABP2p-834 were predicted to have opposite
modifications of the UCP2-8 effect; an effect that is increasingly disparate with addition
of FABP2pID D alleles (see Figure 17 and Figure 18).
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Table 43: Overall Tissue Specific Regression Model for Fat Mass in Females
Term β p-value
Constant 27590 0.000
UCP3-5*FABP3p-313 4092 0.001
r2=0.032
p-value=0.001
Table 44: Overall Tissue Specific Regression Model for Fat Mass (g) in Males
Term β p-value
Constant 25940 0.000
UCP2-8v1 -3955 0.007
PPARg2d*FABP4-2bd -2877 0.007
UCP1-2d*FABP4-2bd 2405 0.027
UCP2-8v2*FABP2pIDv1 -6604 0.002
UCP2-8v2*FABP2pIDv2 -4587 0.002
UCP2-8v1*FABP2p-834v1 3747 0.005
UCP2-8v2*FABP2p-834v1 4240 0.013
r2=0.095
p-value<0.001
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Figure 16: FABP4-2bd modification by PPARg2d and UCP1-2d for adjusted fat mass in
males
Figure 17: UCP2-8 DD modification by FABP2 promoter genotypes for adjusted fat
mass in males
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Figure 18: UCP2-8 DI modification by FABP2 promoter genotypes for adjusted fat mass
in males
The overall model for lean mass in males was also a combination of terms from
the adipose and intestinal models (see Table 45).  The adipose term, an interaction
between FABP4-2bd and UCP2-4, shows that individuals with either the II/TT, -D/CC or
–D/CT multi-locus genotypes (FABP4-2bd/UCP2-4) have an increase of 4kg in their
lean mass compared to the II/CC or II/CT subjects.  Surprisingly, homozygosity for both
of the less common alleles reduces lean mass by ~3kg instead of the expected increase
of ~8kg if the effect were additive (see Figure 19).  In addition to an interaction between
PPARb6d and UCP2-4, the intestinal model also adds an effect of FABP2p-834 that is
modified by both UCP2-4 and UCP2-8.  In individuals with the CC genotype for
FABP2p-834, the T allele appears to reduce lean mass in an additive manner and then
UCP2-8 modifies this effect somewhat (see Figure 20).
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Table 45: Overall Tissue Specific Regression Model for Lean Mass in Males
Term β p-value
Constant 47026 0.000
PPARb6d*UCP2-4v1 -5890 0.001
UCP2-4v2*FABP4-2bd -2503 0.046
UCP2-4v1*FABP2p-834v1 6235 0.005
UCP2-8v1*FABP2p-834v1 -3416 0.033
UCP2-8v2*FABP2p-834v1 -2855 0.039
r2=0.074
p-value=0.001
Figure 19: UCP2-4*FABP4-2b interaction for adjusted lean mass in males
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Figure 20: FABP2p CC modification by UCP2-4/UCP2-8 genotypes for adjusted lean
mass in males
The overall model for lean mass in females again showed the additive
contribution of both the adipose and intestinal tissues to explain a total of 15.5% of the
adjusted trait variation.  This complex model included a single locus effect by FABP4p-
376 and three interactions (UCP1-2d*UCP2-8, UCP1-2*FABP4p-376 and UCP2-
4*UCP2-8) from the adipose tissue as well intestinal effects by UCP2-4, FABP2p-834,
PPARb6d*UCP2-8 and UCP2-4*FABP2p-834 (see Table 46).  The major effect from the
adipose tissue seemed to be due to FABP4p-376 although this effect was compensated
for in UCP1-2 GG subjects (see Figure 21).  UCP2-4 and FABP2p-834 appear to be the
most important site from the intestinal polymorphisms.  The UCP2-4 terms predict a
difference of ~27kg between the two homozygous groups while FABP2p-834 would
show an 18kg difference.  Interactions between the different genotypes at these two
sites, however, compensate for these differences in many individuals.  Individuals with
the TT/CC genotypes (UCP2-4/FABP2p-834) do show a mean lean mass 12kg lower
than TT/TT subjects (see Figure 22).
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Table 46: Overall Tissue Specific Regression Model for Lean Mass in Females
Term β p-value
Constant 54127 0.000
UCP2-4v1 -9599 0.017
UCP2-4v2 -18252 <0.001
FABP2p-834v1 -12933 0.002
FABP2p-834v2 -6702 0.045
FABP4p-376d 7537 <0.001
PPARb6d*UCP2-8v2 -8079 <0.001
UCP1-2d*UCP2-8v2 8151 <0.001
UCP1-2d*FABP4p-376d -7462 <0.001
UCP2-4v1*UCP2-8v1 7735 0.021
UCP2-4v1*FABP2p-834v1 6726 0.047
UCP2-4v2*FABP2p-834v1 21008 <0.001
UCP2-4v2*FABP2p-834v2 15384 <0.001
r2=0.155
p-value<0.001
Figure 21: UCP1-2d*FABP4p-376 interaction for adjusted lean mass in females
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Figure 22: UCP2-4*FABP2p-834 interaction for adjusted lean mass in females
D. Other Analyses
1. PPARb6
Further analysis of the PPARb6 variant was preformed to explore its effect on
fasting glucose, fasting insulin and HOMA IR.  Allele frequencies for PPARb6 in the two
ethnic groups were similar (q=0.137 in H and q=0.127 in NH) and conformed to the
expectations of Hardy-Weinburg equilibrium.  Analysis of variance showed that PPARb6
was significantly associated with fasting glucose (p=0.013), fasting insulin (p=0.034)
and HOMA IR (p=0.013) (see Figure 23, Figure 24, and Figure 25).  Individuals
homozygous for the less common allele of PPARb6 had on average 11 mg/dL lower
fasting glucose, 3 mg/dL lower fasting insulin and 8 units lower HOMA IR when
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compared to the common homozygote.  Regression analysis showed that PPARb6,
sex, and skin reflectance were all significant predictors of ln(fasting glucose) (p<0.001)
while PPARb6 and skin reflectance were both significant predictors of ln(fasting insulin)
(p=0.001) and ln(HOMA IR) (p<0.001) (see Table 47, Table 48, and Table 49).
Figure 23: PPARb6 vs. fasting glucose in SLVDS sample
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Figure 24: PPARb6 vs. fasting insulin in SLVDS sample
Figure 25: PPARb6 vs. HOMA IR in SLVDS sample
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Table 47: Regression Model for ln(Fasting Glucose) in the SLVDS
Term β p-value
Constant 4.82 <0.001
Skin reflectance -0.0035 0.039
Sex -0.068 <0.001
PPARb6 -0.043 0.001
r2=0.056
p>0.0001
Table 48: Regression Model for ln(Fasting Insulin) in the SLVDS
Term β p-value
Constant 2.77 <0.001
Skin reflectance -0.014 0.004
PPARb6 -0.088 0.023
r2=0.019
p=0.001
Table 49: Regression Model for ln(HOMA IR) in the SLVDS
Term β p-value
Constant 3.29 <0.001
Skin reflectance -0.0018 0.002
PPARb6 -0.129 0.006
r2=0.024
p=0.0003
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2. Analysis of PPARγ Polymorphisms
Linkage disequilibrium was calculated for the two polymorphisms in PPARγ,
PPARg2 and PPARg6, which were found to be in high LD (D’=0.767).  In order to
determine the relative contribution of each of the polymorphisms in the PPARγ gene,
PPARg2d and PPARg6d were tested for associations between several outcome
variables that had been adjusted for skin reflectance (fasting glucose, fasting insulin,
HOMA IR, fasting free fatty acids, percent body fat, and fat mass).  No significant
associations between these variables and either of the polymorphisms were found for
males; however, females showed significantly different genotypic means for PPARg6d
in fasting insulin and HOMA IR (see Table 50).  Presence of the PPARg6 T allele
reduced fasting insulin levels by 2.2mg/dL in females CC homozygotes (p=0.008).
Similarly, mean HOMA IR was reduced by almost 5 units in carriers of the PPARg6 T
allele (p=0.007).  After correcting for age, smoking, fat mass, and skin reflectance, linear
regression showed that PPARg6d was a significant predictor of fasting insulin and
HOMA IR while PPARg2d was not.  Models were created for each polymorphism alone
and then with both sites plus the interaction between them.  The PPARg2d models were
not significant and only explained 0.02% (HOMA IR) to 0.04% (fasting insulin) of the
trait variation while both models with only PPARg6d accounted for 1.5% of the variation
in fasting insulin (p=0.031) or HOMA IR (p=0.028).  No significant interactions between
the two sites were observed for either fasting insulin or HOMA IR (see Table 51 and
Table 52).
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Table 50: Genotype Means (±SD) for PPARg2d and PPARg6d vs. outcome variables
adjusted for skin reflectance in females
PPARg2d PPARg6d
CC CG or GG CC CT or TT
Fasting Glucose (mg/dL) 89±19 89±14 90±20 86±10
Fasting Insulin (mg/dL) 11.5±7.3 10.0±5.7 11.7±7.4 9.5±5.0
HOMA IR 17.9±14.9 15.3±11.5 18.4±15.3 13.8±8.6
Free Fatty Acids (µmol/L) 662±245 661±236 663±237 653±253
Percent Fat (%) 42.1±7.2 41.3±7.6 42.2±7.1 41.0±8.0
Fat Mass (kg) 29.2±9.7 29.0±10.1 29.4±9.8 27.8±10.0
N 271 84 244 86
Values in bold represent significantly different means between the genotype groups
(p<0.05).
Table 51: Regression Models for ln(Fasting Insulin) (mg/dL) vs. PPARg2d and
PPARg6d
Models β p-value Constant r2
PPARg2d -0.065 0.268 2.224 0.004
PPARg6d -0.123 0.031 2.240 0.015
PPARg2d 0.114 0.347
PPARg6d -0.109 0.285
g2d*g6d -0.122 0.461
2.233 0.018
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Table 52: Regression Models for ln(HOMA IR) vs. PPARg2d and PPARg6d
Models β p-value Constant r2
PPARg2d -0.057 0.418 2.577 0.002
PPARg6d -0.150 0.028 2.602 0.015
PPARg2d 0.188 0.193
PPARg6d -0.161 0.188
g2d*g6d -0.158 0.426
2.590 0.021
112
V. Discussion
A. Screening and Identification of Variation
The coding regions of exons 2 through 8 in the PPARβ gene were screened
using SSCP and direct sequencing resulting in identification of one new polymorphism
in exon 6.  This substitution of a T for a C (PPARb6) does not alter an amino acid or
restriction enzyme site, but can be detected through an engineered NdeI site.  An
estimated allele frequency of 0.3125 was calculated for the C allele from the eight
screening samples with reliable genotypes.  Approximately 1kb of the region 5’ to exon
1 was also screened for variation although no polymorphisms were identified.  One
kilobase of the promoter region for the PPARγ2 isoform and the putative promoter
region (5’ of exon 1) for PPARα were also screened for genetic variation.  No
polymorphisms were identified in any of these segments.  However, further screening of
the PPARα, PPARβ and PPARγ genes may be warranted since the only newly identified
polymorphism is a silent substitution and other potentially functional regions of the
genes remain unscreened.  This study only looked at the γ2 promoter for the PPARγ
gene, but there could be variation in the γ1, γ3 or γ4 promoters that would alter gene
transcription levels.  In addition, given that PPARγ has four functional promoter regions
as well as four separate transcripts, it is possible that there are also multiple promoters
for PPARα and PPARβ.  Functional characterization of the 5’ putative promoter regions
for these genes is necessary to delineate the regulatory elements for the genes and to
aid in identification of polymorphisms that could alter expression.
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The coding region of RXRα was also screened using SSCP and direct
sequencing in sixteen individuals although no variations were identified.  Recently,
another group screened RXRα for genetic variation and was able to identify three
polymorphisms in the gene (Hegele, 2001).  Two of these sites are intronic, an A to G
substitution in intron 7 at +69bp and a G to A substitution at –25bp in intron 9.  The third
site, a C to T substitution, is found in the 3’ untranslated region at 1470bp.  The intronic
variations were at a frequency of q=0.28 for the A allele of intron 7 +69A/G and q=0.32
for the G allele in intron 9 –25G/A in 30 Caucasian individuals.  The T allele for the 3’-
UTR 1470C/T polymorphism was only found at a frequency of q=0.05 in 20 Caucasians
(Hegele, 2001).  None of these variations are within the regions screened in this project
and the report of their existence was published after the screening and genotyping
phase of the project was complete thus they were not included in any analyses.
B. Genotyping
Seven polymorphisms in the PPARα, PPARβ, PPARγ and RXRβ genes were
identified either from the literature or from screening by SSCP and sequencing.  These
polymorphisms were typed in 764 individuals from the SLVDS population and were all
found to conform to the expectations of Hardy-Weinburg equilibrium in each of the
ethnic groups.  Most of these sites showed similar frequencies in the two ethnic subsets
of the SLVDS although the rare alleles for PPARa6 and RXRb10 showed somewhat
higher frequencies in the Hispanic individuals than in the Non-Hispanic individuals
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(q=0.035 vs. q=0.009 for PPARa6 and q=0.20 vs. q=0.129 for RXRb10).  The allele
frequencies for PPARa5, PPARg2 and PPARg6 found in this study were similar to
previously reported frequencies for these sites in similar populations (Flavell, 2000;
Vohl, 200; Cole, 200; Yen, 1997; Beamer, 1998).
C. Multi-Locus Analysis
1. Descriptive Statistics
Descriptive statistics were calculated for all variables used in the analysis.  The
SLVDS study population was comprised of 42% individuals of Hispanic descent, similar
to the frequency of Hispanic individuals found in the San Luis Valley (43.6%)(Hamman,
1989).  There were similar proportions of males and females in the two ethnic groups
(48% NH male and 45% H male).  Participants were between 34 and 88 years of age
with a mean age of 63 years.  There was a marginally significant difference in the mean
age between Hispanics (62 years) and Non-Hispanics (64 years) although this effect
should not have altered our results since the ethnic groups were either treated
separately or age was adjusted for in the regression model.  Hispanic individuals did
show higher mean values for fasting free fatty acids, triglycerides, fasting glucose,
fasting insulin, and HOMA IR and a lower mean for skin reflectance, as expected.
Interestingly, Non-Hispanics showed increased caloric intake (NH=2016, H=1810;
p=0.001) and fat intake (NH=79, H=71; p=0.015) when compared to Hispanic
individuals (see Table 15).
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2. Univariate Analysis of Outcome and Predictor Variables
Analysis of variance was used to test for associations between the outcome and
continuous predictor variables and the genotypic data.  Two of the original outcomes,
BMI and fat mass, did not show any significant associations with the PPAR or RXR
polymorphisms.  Fasting free fatty acid levels, on the other hand, showed an additive
effect of PPARb6 in the unsplit sample as well as in the Hispanics.  In the Hispanic
group, each T allele decreased FFA levels by ~92µmol/L with a total difference of
185µmol/L between the CC and TT homozygotes.  While not significant, the genotypic
means for PPARb6 were likewise decreasing with addition of each T allele in the Non-
Hispanic group.  It is not surprising that a genotypic effect on FFA would be more
pronounced in the Hispanic group since they have significantly higher mean FFA levels
compared to the Non-Hispanics.  The PPARb6 polymorphism was also found to be
associated with decreased fasting glucose levels in the unsplit sample supporting the
idea that the T allele is in linkage disequilibrium with a protective allele at another site.
The PPARa6 polymorphism was found to have varying effects for different traits.
Heterozygosity for PPARa6 was associated with increased fasting glucose levels in
Non-Hispanics (TT=97, TC=119; p<0.001) but decreased cholesterol levels in Hispanics
(TT=201, TC=185; 0.045).  While the effect on fasting glucose is stronger, there are
only 8 Non-Hispanic heterozygous individuals compared to 20 Hispanic heterozygotes.
When the analysis was preformed for each of the ethnic/gender groups, Non-Hispanic
males heterozygous for PPARa6 showed an even greater increase in fasting glucose
levels compared to the TT homozygous subjects (TT=100, TC=128; p<0.001).  On the
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other hand, the effect on cholesterol in Hispanic females was similar yet only marginally
significant (TT=207, TC=189; 0.052).  Without functional studies of the PPARa6
variation, it is difficult to determine if the C (Ala) allele is detrimental, protective or
actually has different effects in the ethnic groups although the current study leans
toward a detrimental role for the C allele.
In the Hispanic sub-group, the T allele of RXRb+140 was found to have a
dominant effect on cholesterol levels with an increase of ~12 mg/dL over the AA
individuals.  This effect was even more pronounced when only the males were analyzed
showing an increase of ~20mg/dL with the presence of the T allele.  Because this site is
intragenic and has no known effect on RXRβ function, it is possibly in linkage
disequilibruim with another variant in RXRβ or a neighboring gene that has different
frequencies in the two ethnic groups.
Gene-gene interactions were initially examined by two-way analysis of variance.
All pair-wise combinations of the seven polymorphisms were tested against each of the
outcome variables in the seven subject groups.  The Non-Hispanic subset showed a
significant interaction between PPARa5d and PPARb6 for fasting free fatty acids which
could indicate that PPARb6 is important in both ethnic groups, but the effect in Non-
Hispanics is not as strong so that two PPAR variations are required for the same
reduction in FFA levels.  The PPARa5d*PPARb6d interaction was also significantly
associated with cholesterol in the Hispanic individuals.  Several interactions between
the PPARα sites and the PPARγ sites were found for fasting glucose.  PPARa6 had
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significant interactions with both variants in PPARγ for Non-Hispanics while the Hispanic
group showed a significant interaction between PPARa5d and PPARg2d.  The
presence of multiple PPAR interactions could be due to the small effect size of each
polymorphism so that significant alterations in a trait only occur when an individual has
more than one allele with a similar effect (i.e. protective or deleterious).
3. Regression Models
a) PPAR and RXR Models
Regression models were tested with the potentially interesting polymorphisms
determined by analysis of variance in either the PPARs or RXRβ.  Most of the final
models were reduced to one or two significant terms, either single locus effects or
interactions, which explained between 1% and 4% of the variation in the unadjusted
outcome variables.  The Non-Hispanic female model for fasting glucose is a good
example of these simple models.  Individuals homozygous for the common alleles of
PPARb6 and PPARg6 were found to have 6mg/dL higher fasting glucose levels
compared to subjects with at least one of the less common alleles for either site (see
Figure 8).  This model again illustrates the protective nature of the PPARb6 T allele as
well as the T allele for PPARg6 that is in linkage disequilibrium with the G (Ala) allele of
PPARg2.  Other studies have found evidence that the PPARg2 G allele protects against
susceptibility to type-2 diabetes, an association that should be closely related to
reduced fasting glucose levels (Altshuler, 2000).
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Another example of a single term effect was the Hispanic male model for total
cholesterol.  This model predicts that the T allele of RXRb+140d increases total
cholesterol levels by almost 20mg/dL.  The mean cholesterol levels for the AT and TT
individuals were very similar in this group (AT=204mg/dL, TT=206mg/dL vs.
AA=186mg/dL) suggesting that the T allele acts in a dominant manner (see Figure 9).
This single polymorphism, surprisingly, was able to account for over 7% of the variation
in total cholesterol levels in the Hispanic male subjects.  Similarly, RXRb+140d was also
a significant predictor of fasting glucose levels in Hispanic males, along with PPARa5,
PPARg2 and PPARg6.  Various interactions between these four sites were able to
explain 17% of the variation in fasting glucose for that group (see Table 31).  Each of
these variants was found in an interaction with at least two of the other sites possibly
suggesting the presence of higher order interactions that were not tested for in this
analysis.
The model constructed for fasting free fatty acids in the Hispanic females was
also able to account for a large portion of the trait variation (r2=0.110) with only two
terms as significant predictors.  The PPARb6d common homozygote again showed an
increase of 156µmol/L over the T allele carriers although this effect was modified by
homozygosity for the common alleles of both PPARa5d and RXRb+140d that reduced
FFA by 109µmol/L (see Figure 10).
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b) Combined Regression Models
The regression models constructed for fasting free fatty acids and cholesterol
were expanded by adding eleven polymorphisms from the UCPs and FABPs to the
analysis.  A similar method was used by Coleen Damcott to construct models for each
of the outcome variables using the eleven UCP/FABP sites (Damcott, 2002).  These
models combined with the PPAR/RXR models described previously became the basis
for the combined model testing.  Interaction terms between the PPAR/RXR sites and
the UCP/FABP sites were also calculated to look for other potentially interesting terms
to include in the model building.
The Hispanic male model for cholesterol again showed a significant effect of the
RXRb+140d variation as well as an effect by UCP1-2 that was modified by UCP2-8.
Inidividuals with the GG genotype for UCP1-2 and II genotype for UCP2-8 had mean
cholesterol levels of 243mg/dL, an increase of ~53mg/dL over the other genotypes (see
Figure 13).  When the effect of the RXRb+140d T allele is added to this, the GG/II/-T
multi-locus genotype is predicted to have cholesterol levels of 257mg/dL.  These three
polymorphisms were able to account for almost 20% of the variation in cholesterol for
Hispanic males.  It is interesting to note that RXRb+140d and UCP2-8 were both found
to be single locus predictors of cholesterol levels in the separate analyses, but that
UCP1-2 was not in the previous model (see Table 32 and Table 71).
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The model for fasting free fatty acids in Hispanic females was also found to
explain a large portion of the trait variation, 23.4%, and included six terms.  When
considered alone, the A allele for UCP1-2 increases FFA levels by ~90µmol/L over the
GG homozygotes (see Figure 14).  However, three other polymorphisms, FABP3pID,
UCP3p-55 and RXRb+140d, alter the UCP1-2 GG FFA levels to give a range of values
from 839µmol/L in the twelve GG subjects with none of the protective modifying
genotypes to 525µmol/L in the thirteen individuals with all three protective genotypes
(see Figure 15).  The UCP3p-55d*PPARb6d interaction was also a significant predictor
of FFA where individuals homozygous for both alleles were predicted to have FFA
levels 132µmol/L higher than the other genotypes.  This effect appears very similar to
the PPARb6d effect seen previously in the PPAR/RXR models for Hispanic females and
may not actually represent a modification of the PPARb6 effect by UCP3p-55.  Instead,
the PPARb6d*UCP3p-55 interaction could be indicating a higher order interaction
between PPARb6d, UCP3p-55, and UCP1-2 which was not tested.
c) Tissue Specific Regression Analysis
A third set of models was constructed using the polymorphisms in the PPARs,
UCPs and FABPs using fat and lean body mass as outcomes.  These models, unlike
the previous ones, were built around the known expression patterns of the proteins in
three tissue types: muscle, adipose and intestine.  By choosing the isoforms with the
highest expression for each of the tissues and then testing for all possible interactions
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between these sites for a given tissue, a more biologically meaningful final model may
have been achieved.  This analysis plan allowed for detection of multiple interactions
that are interdependent and not necessarily significant as seen in a two-way analysis of
variance.  Another advantage of this method was that, for this study, it was less time
consuming since the initial determination of potential loci to include in the regression
analysis was unnecessary.
Three of the four overall final models constructed (lean mass in males, lean mass
in females and fat mass in males) were combinations of the adipose and intestinal final
models.  The female overall model for fat mass only included a single term from the
muscle specific model since the adipose and intestinal models did not retain any
significant terms.  In this case, other genes seem to be having a larger effect on fat
mass in females since no major effect was noted here although higher order
interactions between the tested polymorphisms is a possibility.  The male fat mass
model, a combination of the adipose and intestinal models, was able to explain 9.5% of
the variation in adjusted fat mass.  The contributions from adipose and intestinal models
to the overall model each illustrate multi-locus gene effects.  The adipose terms show
an effect by FABP4-2bd that is modified by both UCP1-2d and PPARg2d (see Figure
16).  UCP2-8 from the intestinal model was also a major predictor of fat mass in males
with a modified effect from the FABP2 promoter polymorphisms (see Figure 17 and
Figure 18).  It is interesting to note that the two variants in the FABP2 promoter had
opposing effects on fat mass and thus would cancel each other out in many haplotypes.
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The overall tissue model for lean mass in males also showed a significant
interaction between UCP2-8 and FABP2p-834 although this was counteracted by a
UCP2-4*FABP2p-834 interaction instead of UCP2-8*FABP2pID (see Figure 20).  In
addition, UCP2-4 modified the adipose FABP4-2b effect (see Figure 19).  The complex
model constructed for lean mass in females again showed an interaction between
UCP2-4 and FABP2p-834, the two terms that showed the greatest effect in the final
model (see Figure 22).  The adipose model terms in the final overall model included
interactions between UCP1-2 and FABP4p-376, UCP1-2 and UCP2-8 as well as UCP2-
4*UCP2-8 (see Figure 21).
The most interesting observation from these models is that combinations of
adipose and intestinal genes seem to be significantly influencing lean body mass.  In
fact, no significant predictors of lean mass were found in the list of sites tested for
muscle in females.  Likewise, all of the terms were removed from the female adipose
model for fat mass.  Given that there is overlap in gene expression, the other genes
designated as being primarily in another tissue could still be present in either the muscle
or fat at levels capable of altering lean or fat mass.  In addition, variations in PPAR,
RXR, UCP or FABP function in any tissue could potentially alter whole body
homeostasis and thereby alter traits in seemingly distant tissues.  For example, mice
that overexpress UCP3 in their muscles show, in addition to reduced lean mass,
reductions in adipose mass, insulin, glucose and cholesterol levels (Clapham, 2000).
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D. Other Analyses
1. PPARb6
Further analysis of the PPARb6 variant found that it is associated with fasting
levels of glucose and insulin as well as insulin sensitivity measured by HOMA IR.
Specifically, the T allele corresponded to lower glucose and insulin levels and therefore
greater insulin sensitivity in normoglycemic individuals.  Knowing that this population is
of mixed sex and ethnic background, regression models were constructed to include
sex and skin reflectance as covariates.  Regression analysis confirmed that PPARb6 is
a significant predictor of phenotypic variation even when sex and skin reflectance are
taken into account.  These results repeat the PPARb6 T allele effect seen in the
regression analysis (see Sections C.2 and C.3.a) lending support to the idea that the T
allele is protective.  The results from this study overall suggest a role for PPARβ in
glucose regulation and insulin metabolism independent of sex and ethnicity in this
population.  A more exhaustive screening of the PPARβ gene would be useful in order
to determine if there are other functional polymorphisms in linkage disequilibrium with
the PPARb6 variant.
2. Analysis of PPARγ Polymorphisms
Knowing that PPARg2 and PPARg6 are in high linkage disequilibrium (D’=0.767
for this study) and that PPARg6 is a silent substitution and likely non-functional, it has
been assumed by many that PPARg6 is merely a marker for PPARg2 and is useful
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because of it’s increased frequencies in some populations.  However, the multi-locus
regression analysis results from this study found PPARg6 present in eight different final
models while PPARg2 only appeared in three models, two of which contained the
PPARg2d*PPARg6d interaction.  As the functional polymorphism, PPARg2 should have
been a better predictor of any trait that it is influencing, especially since the frequencies
were similar between the two ethnic groups.  Another study also found evidence of an
interaction between these sites by observing that there was a greater difference in BMI
and fat mass between the common and rare double homozygous individuals compared
to the difference in homozygotes when the polymorphisms were considered separately
(Valve, 1999).  The results from the current study in combination with the findings from
other groups suggested the possibility that PPARg6 is actually marking another
functional variant in the PPARγ gene region.  Further analysis of these two
polymorphisms revealed that the T allele of PPARg6 is associated with a significant
reduction in fasting insulin levels and HOMA IR in females (see Table 50, Table 51, and
Table 52).  This effect was small, 2.2mg/dL for FI and 4.6 units for HOMA IR, but was
highly significant (p=0.008 and p=0.007, respectively).  This association was still
present after adjustment for age, smoking, fat mass and skin reflectance, but was not as
strong (p=0.031 for FI and p=0.028 for HOMA IR).  However, PPARg6d did explain a
greater amount of variation in these traits compared to PPARg2d (r2=0.015 for g6d vs.
r2≈0.003 for g2d).  No significant interactions between the two sites were observed for
these traits.
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In this population, PPARg6d appears to be a better predictor than PPARg2d of
fasting insulin levels and insulin resistance although the effect of this variant is small.
This supports the hypothesis that PPARg6 may be in linkage disequilibrium with another
functional variant other than PPARg2.  If true, this could help to explain some of the
inconsistencies in the PPARγ association studies since another functional polymorphism
in the region could be at a different frequency or level of linkage disequilibrium with
PPARg2 for various populations.  This possibility has already been proposed by Hegele,
et al, who found that the G (ala) allele for PPARg2d was associated with increased
susceptibility to type-2 diabetes in a Canadian Indian population which conflicted with
the findings of many other studies (Hegele, 2000).
E. Conclusions
The PPARb6 polymorphism identified in this study was found to be associated
with multiple obesity and diabetes related traits.  The less common T allele showed a
protective effect on fasting free fatty acids, fasting glucose, fasting insulin and HOMA IR
in many different analyses.  The magnitude and frequency of the PPARb6 effect in this
population strongly suggests that the T allele is in linkage disequilibrium with another
functional variant with increased activity that provides this protective effect.  The
PPARg6 T allele was also found to have a protective effect on several traits, although
not as strong as the PPARb6 effect.  The reduction in insulin and HOMA IR seen in the
PPARg6 TT individuals is not likely to be caused by the potentially protective nature of
126
the PPARg2 G allele since g2 itself was not an important predictor for these traits.  If
PPARg2 were actually influencing these traits, it should show a greater effect than the
non-functional PPARg6 because of lower noise.  It is interesting to note that the less
common alleles in all three of these sites appear to be associated with lower risk
phenotypes for obesity and type-2 diabetes related traits.
Comparison of the PPAR/RXR models with the combined models including the
FABPs and UCPs shows that consideration of more polymorphisms for a regression
model leads to stronger models that explain more variation.  The PPAR/RXR model for
cholesterol in Hispanic males predicted that the T allele of RXRb+140 increases
cholesterol levels by approximately 20mg/dL while the UCP/FABP model showed an
effect by only UCP2-8.  The overall model replicated these results but added another
polymorphism, UCP1-2, so that together, these three sites were able to explain almost
20% of the variation in cholesterol.  Similarly, the Hispanic female model for fasting free
fatty acid repeated some of the terms from the previous models, but, by adding
interactions between the PPARs, RXRs and UCPs, was able to explain 23.4% of the
trait variation.
These models exemplify the effect of multi-locus genotypes on quantitative traits,
but are they consistent with previous single gene studies?  No association studies have
been published for three of the sites seen in these two models (PPARb6, RXRb+140
and FABP3pID), but their effects have been mostly consistent within this study when
they were seen as a single gene effect.  Hamann et al (1998) found that the A allele of
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UCP1-2 was more prevalent in obese children compared to lean subjects possibly
linking it to increases in body fat.  The UCP1-2 term is a significant predictor in the
Hispanic male model for cholesterol although its effect only appears in conjunction with
UCP2-8 (see Figure 13).  In the Hispanic female model for fasting free fatty acids, the
UCP1-2 A allele is associated with increased FFA levels which is consistent with
increased adiposity (see Figure 14).  The I allele of UCP2-8 has been associated with
increased BMI in several studies which is consistent with it’s predicted effect in the
Hispanic male model for cholesterol (Cassell, 1999; Walder, 1998) (see Figure 13).  In
the case of UCP3p-55, skeletal muscle from non-diabetic Pima Indians showed
increased mRNA levels in individuals with the T allele of UCP3p-55 (Schrauwen, 1999).
Increased UCP3 mRNA levels should correlate with increased UCP activity that could
lead to lower fasting free fatty acids.  However, the CC genotype appears to be lowering
fasting free fatty acids in the UCP1-2 GG individuals in the Hispanic female model for
FFA.  Since UCP3p-55 is only seen in interactions in this model, its direct effect may be
difficult to separate from the other polymorphisms.
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F. Implications and Future Studies
This study tested several regression modeling methods for determining multi-
locus genotype predictors of quantitative traits related to obesity and type-2 diabetes.
Because this was an exploratory analysis, no correction for multiple testing was used in
the analysis.  Therefore, the results need to be interpreted with caution.  The
conclusions from this study are primarily based on repeated, consistent results from the
different analyses.  Still, this study does provide a foundation for further research into
multi-locus genotype analysis and suggests a role for the PPAR pathway in obesity and
diabetes.
There are many potential studies that would be useful in confirming the results of
this study.  A major priority would be to re-screen the genes encoding PPARβ and
RXRβ in an attempt to identify functional variation.  Further screening in individuals
homozygous for the less common allele at either PPARb6 or RXRb+140 would increase
the chances of finding a functional polymorphism in linkage disequilibrium with the sites
used in this analysis.  This approach would be more effective than screening random
samples because it would increase the number of carriers of an unidentified
polymorphism in high linkage disequilibrium with the previously identified sites.
Replication of parts of the analysis in other populations would help to confirm the
effects of the different polymorphisms either alone or in combination.  For example, it
would be interesting to test the Hispanic male model for cholesterol that included effects
from RXRb+140, UCP1-2, and UCP2-8 in another larger, unrelated, Hispanic
129
population.  Analysis of a larger population would allow for comparison of more
individuals in each of the genotype groups.  This would help to clarify whether the
apparent sex specific effect is real or is undetectable in the small number of Hispanic
females in this study.  Given that the size of the Hispanic female group is slightly larger
than the Hispanic male group, it is possible that both of these options are true.  If the
effect is reduced in females as compared to males, then it could be undetectable in our
population and apparent in another larger study.  Several of the other models would be
worth further analysis as well, including the Hispanic female model for fasting free fatty
acids from the combined analysis and the overall models from the tissue specific
analysis.
Another potential direction for this study would be to use other multi-locus
genotype analysis techniques such as CPM or MDR on the SLVDS population.
Principal component analysis would be another interesting approach to analyzing this
data given the collinearity within the genetic data.  Re-analysis of this data by different
techniques would be interesting to determine the consistencies, strengths and
weaknesses of the various methods.  Side by side comparison with other analysis
methods would also be useful in developing and refining the regression model approach
used in this study.
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G. Summary
This study illustrates the importance of examining multiple polymorphisms in
genes with inter-related functions in order to understand their full contribution to a given
trait.  Multi-locus genotypes were almost always the best predictor of a trait and were
often able to explain large portions of the variation.  In the long run, analysis techniques
developed specifically to test multi-locus genotype will be a powerful tool in determining
the genetic influences on complex traits and disorders, but for now, modifications of
more traditional methods that allow for multi-locus effects are likely to provide a better
understanding of disease related polymorphisms than simple single locus analysis.
APPENDICES
132
Appendix A
Single Stranded Nuceotide Polymorphism (SSCP) Protocol
1. Clean and label the gels before attaching them to the gel box.  Fill behind the gels
with 1 x TBE buffer.
2. Combine 7.5µL of amplified DNA with 3.75µL of denaturing solution then incubate
at 42oC for 10 minutes.
3. Put samples on ice immediately when finished with the 42oC incubation then add
3.75µL of formamide dye to each reaction.
4. Load all 15µL of the denatured/stained sample into a well using a fine pipette tip.
5. Run the gel at 150 volts until the dye is run off the gel or until the bands are
sufficiently separated.
6. Remove the gels from the casing and stain with SYBR Green II RNA Gel Stain for
20 to 30 minutes depending on the freshness of the reagent.  Gels and stain should
be kept in the dark and mildly agitated.
7. Rinse the gels with dH2O then photograph gel using UV fluorescence to visualize
the bands.
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Solutions Used in SSCP
SYBR Green II RNA Gel Stain (Molecular Probes Inc., Catalog #S-7586)
Dilute 1:10,000 by adding 4µL to SYBR Green stain to 50µL of 1xTBE
Keep solution in the dark
Stain can be used 2 to 3 times
Formamide Dye
10ml formamide
5mg Xylene Cyanol (0.05%)
5mg Bromophenol Blue (0.05%)
200µL EDTA (0.5M)
store at –20oC
Denaturing Solution (NaOH/EDTA)
200µL EDTA (0.5M)
5ml NaOH (1M)
4.8ml dH2O
store at –20oC
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Appendix B
Oligonucleotide Ligation Assay (OLA) Protocol
1. Dilute PCR samples with 0.1% triton water. (1:1 or 50:20 water to sample)
2. Get out strepavidin plates to warm and make 0.5% BSA in PBS
0.25g BSA in 50mls of PBS (50mls is enough for 2 OLA plates)
3. Make up OLA reaction mix, one for each allele.
# PCR trays (# OLA) 1 tray (2)
NAD 240 ul
10X Ligase Buffer 240 ul
0.1% triton water 690 ul
1M KCl 30 ul
unique oligo 4 ul
common oligo 4 ul
ampligase 4 ul
Oligos should be kept at a stock conc of 50uM and diluted to 5uM each day.
4. Place 10 ul of reaction mix for allele A into the odd rows of a 96-well plate and 10 ul
of allele B into the even rows.  Two 96-well plates are needed for each PCR tray in
a 2 allele system.
5. Place 10 ul of diluted PCR product into the OLA plates.  Row 1 of the PCR tray
goes into rows 1 and 2 of the OLA plate.  Row 2 of the PCR goes into rows 3 and 4
of the OLA plate.  Overlay with oil if necessary.
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6. Ligation reaction – 10 cycles of 93˚C for 30s and 58˚C for 2 min.
7. After ligation reaction is started, block the strepavadin plates.  Empty plate in sink
then dry by tapping on paper towels.  Add 200 ul/ well of 0.5% BSA in PBS.  Let sit
at RT for at least 30 min.
8. To stop the ligation reation, add 10 ul of 0.1M EDTA and 0.1% triton water to each
well.  Add as soon as possible after the ligation reaction has finished cycling to
avoid non-specific ligation.
9. Wash blocked strepavadin plates once with Tris Wash.
10. Capture phase - Transfer all of the ligation reaction, including the oil, to the
strepavadin plates and allow to sit at RT for at least 30 min and up to 3 hours.
11.  About 15 min before the end of the capture phase get out ELISA reagents and
dilute the antibody.  4 mls of antibody soltion are needed for each OLA plate.  1ul of
antibody is diluted into 1 ml of 0.5% BSA in PBS.
12.  Remove the reaction mix from the strepavadin plates with the plate washer then
wash the OLA plates 2X with NaOH wash and 2X with Tris wash.  Approximately 40
mls of NaOH wash are needed per OLA plate.
13.   Add 40 ul of anitbody solution to each well and let sit at RT for at least  25 min but
no more than 30 min.
14.   Prepare substrate and amplifier solutions by adding the vial of liquid to the vial with
powder in it.  Each vial will do about 4 OLA plates.
15.   Wash the OLA plates 6X with Tris wash.
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16.   Add 25 ul of substrate to each well and let sit at RT for about 15 min.
17.   Add 25 ul of amplifier to each well.  Color change should begin within a few
minutes.
18.   When the color has reached a good intensity, add 25 ul of 0.3M H2SO4 to stop the
reaction before the background builds up too much.
Solutions Used
100mM NAD
0.663g NAD into 10mls of dH2O
store at –20˚C in 1ml aliquots
1M Tris-HCl at pH 8.0
60.55g Tris
upto 500 mls with dH2O
pH to 8.0 with HCl
10X Ligase Buffer
10 mls of 1M Tris HCl (8.0)
1.02g MgCl2
0.134g DTT
upto 50mls with dH2O
store at –20˚C in 1ml aliquots
0.1% Triton Water
50uls of triton-X 100 in 50mls of dH2O
Phosphate Buffered Saline (PBS)
8g NaCl
0.2g KCl
1.44g Na2HPO4
0.24g KH2PO4
upto 1L with dH2O
filter before use
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1M KCl
3.725g KCl
upto 50mls with dH2O
NaOH Wash
25mls 1M NaOH
125ul Tween 20
upto 250mls with dH2O
10X Tris Wash
121.1g Tris (to 1M)
87.6g NaCl
upto 1 L with dH2O
1X Tris Wash
200mls 10X Tris Wash
1ml Tween 20
upto 2 L with dH2O
Stop Solution
50mls 0.5M EDTA
250mls Triton-X 100
upto 250mls with dH2O
Strepavidin Plates
1.25mls of 1mg/ml strepavidin
upto 50 mls with 1X PBS
add 50ul of diluted strepavidin to each well
store at 4˚C for upto 6 months
(use Falcon plates 3075)
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Appendix C
Descriptive Statistics
Table 53: Frequencies of categorical variables in SLVDS population including outliers
Category Frequency
Non-smoker 49.9
Current smoker 14.1
Smoking
Status
Ex-smoker 36.0
Male 45.5Sex
Female 54.5
Non-Hispanic 57.8Ethnicity
Hispanic 42.2
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Table 54: Descriptive statistics of continuous variables including outliers
Variables Mean±SD Skewness Kurtosis N
BMI (kg/m2) 27.3±4.9 0.743 1.299 763
Fat Mass (kg) 26.2±9.3 0.455 0.416 712
% Body Fat (%) 35.4±9.6 -0.112 -0.537 712
Lean Mass (kg) 44.7±10.8 0.427 -0.855 712
Fasting FFA (µmol/L) 603±244 0.777 0.936 762
Cholesterol (mg/dl) 201±36 0.371 0.615 762
Triglycerides (mg/dl) 181±104 2.958 16.679 762
Fasting Glucose (mg/dl) 101±27 5.550 47.801 762
Fasting Insulin (mg/dl) 11.2±6.6 1.980 5.060 762
HOMA IR 17.7±14.0 3.142 16.681 762
Systolic BP (mm) 127±18 1.115 2.344 762
Diastolic BP (mm) 74±9 0.320 0.736 762
Caloric Intake (cal) 1957±940 2.292 13.887 729
Fat Intake (g) 76.9±49.3 4.219 46.768 729
Physical Activity (kCal/kg/hr) 285±68 2.288 6.572 741
Age (years) 63±12 -0.156 -0.782 763
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Figure 26: Histograms for continuous variables without outliers
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Appendix D
Predictor Correlations
Table 55: Correlation coefficients for outcome and predictor variables
B
M
I
P
F
T
F
M
LM F
F
A
C
H
L
T
R
G
F
G F
I
H
IR
S
K
R
P
A
A
G
E
S
M
K
BMI - .563 .862 .296 .105 -0.7 .183 .225 .499 .457 .011 .011 -.11 .016
PFT .563 - .824 -.51 .323 .124 .119 .027 .327 .273 .046 -.28 -.03 -.14
FM .862 .824 - .025 .190 .001 .166 .149 .452 .400 .082 -.13 -.12 -.04
LM .296 -.51 .025 - -.32 -.18 .076 .179 .085 .103 .054 .306 -.15 .206
FFA .105 .323 .190 -.32 - .131 .176 .184 .170 .198 -.06 -.16 .206 -.01
CHL -.07 .124 .001 -.18 .131 - .261 -.02 -.06 -.06 -.03 -.07 .032 -.02
TRG .183 .119 .166 .076 .176 .261 - .269 .298 .309 -.08 .020 -.08 .051
FG .225 .027 .149 .179 .184 -.02 .269 - .349 .618 -.07 .057 .071 .075
FI .499 .327 .452 .085 .170 -.06 .298 .349 - .934 -.10 -.11 -.01 .019
HIR .457 .273 .400 .103 .198 -.06 .309 .618 .934 - -.10 -.07 .011 .029
SKR .011 .046 .082 .054 -.06 -.03 -.08 -.07 -.10 -.10 - .037 .102 -.08
PA .011 -.28 -.13 .306 -.16 -.07 .020 .057 -.11 -.07 .037 - -.21 .047
AGE -.11 -.03 -.12 -.15 .206 .032 -.08 .071 -.01 .011 .102 -.21 - .023
SMK .016 -.14 -.04 .206 -.01 -.02 .051 .075 .019 .029 -.08 .047 .023 -
Abbreviations: BMI – body mass index (kg/m2); PFT – percent body fat (%); FM – fat
mass (g); LM – lean mass (g); FFA – fasting free fatty acids (µmol/L); CHL – cholesterol
mg/dL); TRG – triglycerides (mg/dL); FG – fasting glucose (mg/dL); FI - fasting insulin
(mg/dL); HIR – HOMA IR; SKR – skin reflectance (%); PA – physical activity
(kCal/kg/hr); AGE – age at phase IV visit (years); SMK – smoking.
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Table 56: Polymorphism vs. polymorphism significance level for Pearson Χ2 test
PPARa5 PPARa6 PPARb6 PPARg2 PPARg6 RXRb10 RXRb+140
PPARa5 - 0.295 0.090 0.378 0.918 0.007 0.332
PPARa6 0.295 - 0.331 0.210 0.311 0.696 0.507
PPARb6 0.090 0.331 - 0.171 0.008 0.864 0.504
PPARg2 0.378 0.210 0.171 - <0.001 0.061 0.054
PPARg6 0.918 0.311 0.008 <0.001 - 0.015 0.812
RXRb10 0.007 0.696 0.864 0.061 0.015 - <0.001
RXRb+140 0.332 0.507 0.504 0.054 0.812 <0.001 -
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Appendix E
Final Regression Models for PPAR/RXR Analysis
Table 57: Final regression model for fasting free fatty acids (µmol/L) in the unsplit
sample
Term β p-value
Constant 497 0.000
PPARb6v1 111 0.042
PPARb6v2 58 0.311
r2=0.013
p-value=0.011
Table 58: Final regression model for fasting free fatty acids (µmol/L) in Non-Hispanics
Term β p-value
Constant 563 0.000
RXRb+140v2 104 0.031
RXRb10d*RXRb+140v2 -119 0.019
r2=0.016
p-value=0.061
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Table 59: Final regression model for fasting free fatty acids (µmol/L) in Hispanics
Term β p-value
Constant 609 0.000
PPARb6d 108 0.004
PPARa6*PPARg6d -70 0.028
r2=0.052
p-value=0.001
Table 60: Final regression model for fasting free fatty acids (µmol/L) in Non-Hispanic
males
Term β p-value
Constant 468 0.000
PPARa5d*PPARb6d 53 0.066
r2=0.018
p-value=0.066
Table 61: Final regression model for ln(fasting glucose) (mg/dL) in the unsplit sample
Term β p-value
Constant 4.372 0.000
PPARa6 0.158 0.008
PPARb6d 0.050 0.002
PPARg6d 0.188 0.018
PPARa6*PPARg6d -0.163 0.029
r2=0.026
p-value=0.002
147
Table 62: Final regression model for ln(fasting glucose) (mg/dL) in Non-Hispanics
Term β p-value
Constant 4.422 0.000
PPARa6 0.112 0.038
PPARa6*PPARb6d 0.038 0.029
r2=0.030
p-value=0.003
Table 63: Final regression model for ln(fasting glucose) (mg/dL) in Hispanics
Term β p-value
Constant 4.603 0.000
RXRb10d*RXRb+140v2 0.069 0.024
r2=0.021
p-value=0.024
Table 64: Final regression model for ln(fasting glucose) (mg/dL) in Non-Hispanic males
Term β p-value
Constant 4.561 0.000
PPARb6d 0.058 0.024
r2=0.027
p-value=0.024
Table 65: Final regression model for cholesterol (mg/dL) in Non-Hispanics
Term β p-value
Constant 192.5 0.000
PPARa5d*PPARa6 10.3 0.022
r2=0.012
p-value=0.022
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Table 66: Final regression model for cholesterol (mg/dL) in Hispanics
Term β p-value
Constant 206.9 0.000
PPARa6*RXRb+140d -12.6 0.002
r2=0.040
p-value=0.002
Table 67: Final regression model for cholesterol (mg/dL) in Non-Hispanic Females
Term β p-value
Constant 209.2 0.000
RXRb10d*RXRb+140d -12.7 0.034
r2=0.026
p-value=0.034
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Appendix F
Regression Model Summary for UCPs and FABPs
Table 68: Regression Model Summary for Non-Hispanic Females
Outcome Variable Genotype Terms p-value r2
Fat Mass UCP2-4*UCP3-5 <0.001 0.133
Fasting Free Fatty Acids UCP2-4*UCP3-5 0.002 0.058
ln(Triglycerides) UCP3p-55*FABP3p-ID 0.001 0.053
Cholesterol
UCP3p-55
FABP2p-ID
UCP3p-55*FABP3p-ID
0.002 0.075
ln(HOMA IR)
UCP3-5*FABP3p-313
UCP3p-55*FABP3p-313
0.003 0.056
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Table 69: Regression Model Summary for Non-Hispanic Males
Outcome Variable Genotype Terms p-value r2
Fat Mass
FABP2p-ID
FABP3p-ID
UCP1-2*FABP3p-ID
UCP2-8*FABP3p-ID
FABP2p-ID*FABP4p-376
FABP3p-ID*FABP4p-376
<0.001 0.226
Fasting Free Fatty Acids FABP3p-ID 0.031 0.023
ln(Triglycerides)
UCP3p-55*FABP3p-ID
UCP3-5*FABP2p-ID <0.001 0.076
Cholesterol FABP3p-313 0.050 0.019
ln(HOMA IR)
FABP2p-ID
FABP3p-ID
FABP2p-ID*FABP3p-ID
0.044 0.057
Table 70: Regression Model Summary for Hispanic Females
Outcome Variable Genotype Terms p-value r2
Fat Mass
UCP1-2
UCP3-5
UCP1-2*UCP3-5
<0.001 0.122
Fasting Free Fatty Acids
UCP1-2*UCP3p-55
UCP1-2*FABP3p-ID
UCP3p-55*FABP3p-ID
<0.001 0.117
ln(Triglycerides)
UCP1-2
UCP1-2*UCP2-8
0.002 0.074
Cholesterol UCP3-5*FABP3p-ID 0.001 0.071
ln(HOMA IR)
UCP2-8
UCP3p-55*FABP2p-834 0.061 0.034
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Table 71: Regression Model Summary for Hispanic Males
Outcome Variable Genotype Terms p-value r2
Fat Mass UCP1-2*FABP2-2 0.009 0.054
Fasting Free Fatty Acids
UCP2-4
UCP2-8 0.001 0.096
ln(Triglycerides) UCP3-5*FABP3p-313 0.010 0.049
Cholesterol UCP2-8 0.018 0.058
ln(HOMA IR) No Model
152
Appendix G
Final Regression Models for Combined Analysis
Table 72: Final combined regression model for fasting free fatty acids (µmol/L) in Non-
Hispanic males
Term β p-value
Constant 466.2 0.000
PPARa5d*PPARb6d 78.2 0.035
PPARb6d*FABP3pIDv1 -76.5 0.070
PPARb6d*FABP3pIDv2 6.2 0.876
r2=0.054
p-value=0.018
Table 73: Final combined regression model for fasting free fatty acids (µmol/L) in Non-
Hispanic females
Term β p-value
Constant 627.8 0.000
PPARg6d 170.6 0.038
PPARa5d*FABP3pIDv1 -35.6 0.547
PPARa5d*FABP3pIDv2 -98.3 0.039
PPARg6d*UCP3-5v1 34.2 0.509
PPARg6d*UCP3-5v2 -128.0 0.012
PPARg6d*FABP3pIDv1 -154.9 0.068
PPARg6d*FABP3pIDv2 -5.4 0.941
r2=0.139
p-value>0.001
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Table 74: Final combined regression model for fasting free fatty acids (µmol/L) in
Hispanic males
Term β p-value
Constant 559.0 0.000
UCP2-4v1 -43.2 0.561
UCP2-4v2 154.2 0.009
UCP2-8v1 -27.3 0.774
UCP2-8v2 -136.1 0.142
r2=0.101
p-value=0.008
Table 75: Final combined regression model for cholesterol in Non-Hispanic males
Term β p-value
Constant 216.2 0.000
PPARb6d -27.9 0.014
PPARg6d -33.4 0.009
PPARg6d*RXRb10d 23.8 0.033
PPARb6d*UCP1-2 34.2 0.001
PPARg6d*FABP2p-834v1 18.7 0.039
PPARg6d*FABP2p-834v2 5.5 0.531
RXRb10d*UCP1-2 -26.3 0.005
r2=0.0.094
p-value=0.025
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Table 76: Final combined regression model for cholesterol in Non-Hispanic females
Term β p-value
Constant 197.8 0.000
FABP2pIDv1 5.2 0.487
FABP2pIDv2 -7.6 0.271
PPARa5d*UCP3-5v1 15.9 0.010
PPARa5d*UCP3-5v2 12.5 0.039
r2=0.0.064
p-value=0.009
Table 77: Final combined regression model for cholesterol in Hispanic females
Term β p-value
Constant 182.9 0.000
UCP2-8v1 24.5 0.068
UCP2-8v2 -2.9 0.820
UCP3-5v1*FABP3pIDv1 7.8 0.391
UCP3-5v1*FABP3pIDv2 34.4 0.000
UCP3-5v2*FABP3pIDv1 9.4 0.309
UCP3-5v2*FABP3pIDv2 0.7 0.920
PPARg6d*UCP2-8v1 -9.0 0.383
PPARg6d*UCP2-8v2 22.4 0.019
r2=0.157
p-value=0.002
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Appendix H
Regression Model Summary for Lipid Variables in Tissue Specific Analysis
Table 78: Cholesterol Tissue Specific Regression Model Summary for Males
Tissue Genotype Terms p-value r2
Muscle FABP3p-313 0.025 0.015
Adipose UCP2-8*FABP4p-376 0.031 0.014
Intestine No Model
Overall UCP2-8*FABP4p-376 0.034 0.014
Table 79: Cholesterol Tissue Specific Regression Model Summary for Females
Tissue Genotype Terms p-value r2
Muscle
FABP3p-313
PPARa5*UCP3-5
FABP3p-ID*FABP3p-313
0.006 0.036
Adipose No Model
Intestine
UCP2-8
UCP2-4*UCP2-8
UCP2-4*FABP2p-834
0.039 0.030
Overall
UCP2-8
FABP3p-313
UCP2-4*UCP2-8
UCP2-4*FABP2p-834
FABP3p-ID*FABP3p-313
0.002 0.061
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Table 80: Triglycerides Tissue Specific Regression Model Summary for Males
Tissue Genotype Terms p-value R2
Muscle
FABP3p-313
UCP3-5*UCP3p-55
0.005 0.033
Adipose
FABP4-2b
UCP2-4*FABP4-2b
UCP2-4*FABP4p-376
UCP2-8*FABP4-2b
UCP2-8*FABP4p-376
0.005 0.065
Intestine UCP2-4*FABP2p-ID 0.012 0.020
Overall
UCP2-4
FABP4-2b
UCP2-4*FABP2p-ID
UCP2-4*FABP4-2b
UCP2-4*FABP4p-376
UCP2-8*FABP4-2b
UCP2-8*FABP4p-376
0.003 0.075
Table 81: Triglycerides Tissue Specific Regression Model Summary for Females
Tissue Genotype Terms p-value r2
Muscle No Model
Adipose
UCP2-4
PPARg2*UCP2-4
PPARg2*UCP2-8
UCP1-2*UCP2-4
UCP1-2*UCP2-8
<0.001 0.080
Intestine UCP2-4 0.007 0.020
Overall
UCP2-4
PPARg2*UCP2-4
PPARg2*UCP2-8
UCP1-2*UCP2-4
UCP1-2*UCP2-8
<0.001 0.080
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Table 82: Fasting Free Fatty Acids Tissue Specific Regression Model Summary for
Males
Tissue Genotype Terms p-value r2
Muscle No Model
Adipose
UCP1-2
UCP2-4
UCP2-8
UCP1-2*UCP2-8
UCP2-4*FABP4-2b
UCP2-8*FABP4-2b
0.003 0.074
Intestine
UCP2-4
FABP2p-834
PPARb6*FABP2p-834
UCP2-4*UCP2-8
UCP2-8*FABP2p-834
UCP2-8*FABP2p-ID
0.006 0.065
Overall
UCP1-2
UCP2-4
UCP2-8
UCP1-2*UCP2-8
UCP2-4*FABP4-2b
UCP2-8*FABP4-2b
0.003 0.074
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Table 83: Fasting Free Fatty Acids Tissue Specific Regression Model Summary for
Females
Tissue Genotype Terms p-value R2
Muscle PPARa5*UCP3-5 0.010 0.018
Adipose
UCP1-2
FABP4-2b
PPARg2*UCP2-8
PPARg6*UCP1-2
UCP1-2*UCP2-8
UCP2-4*FABP4-2b
0.008 0.058
Intestine
FABP2p-ID
FABP2p-834
UCP2-4*FABP2p-ID
UCP2-4*FABP2p-834
UCP2-8*FABP2p-ID
UCP2-8*FABP2p-834
0.001 0.090
Overall
UCP1-2
FABP2p-ID
PPARa5*UCP3-5
UCP1-2*UCP2-8
UCP2-4*FABP2p-ID
UCP2-4*FABP2p-834
UCP2-8*FABP2p-ID
UCP2-8*FABP2p-834
<0.001 0.113
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